

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020



CONTENTS

Introduction	1
New or Updated Recommendations	2
Methods.....	2
HAV Background.....	3
Prophylaxis Against HAV Infection.....	11
Recommendations for Hepatitis A Vaccine and Immune Globulin for Preexposure Prophylaxis.....	17
Future Directions.....	24
References	24
Appendix A: Provider Guidance for Preexposure Protection for International Travelers Aged ≥12 Months	35
Appendix B: Provider Guidance on Risk Assessment for Hepatitis A Postexposure Prophylaxis.....	36

CDC Adoption of ACIP Recommendations for *MMWR* Recommendations and Reports, *MMWR* Policy Notes, and Immunization Schedules (Child/Adolescent, Adult)

Recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of CDC on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States. Recommendations for routine use of vaccines in children and adolescents are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG). Recommendations for routine use of vaccines in adults are harmonized with recommendations of AAFP, ACOG, and the American College of Physicians (ACP). ACIP recommendations approved by the CDC Director become agency guidelines on the date published in the *Morbidity and Mortality Weekly Report (MMWR)*. Additional information is available at <https://www.cdc.gov/vaccines/acip>.

Disclosure of Relationships

All 2019 Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group members have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Dr. Kelly L. Moore reports personal fees from Prime, Inc., and from Pfizer, outside the submitted work. The remaining members have no financial or competing interests with the manufacturers of commercial products or suppliers of commercial services related to hepatitis A (HepA) vaccines. Content will not include any discussion of the unlabeled use of a product or a product under investigational use, with the following exception: administration of HepA vaccine to infants aged 6–11 months traveling outside the United States when protection against HAV is recommended.

The *MMWR* series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. *MMWR Recomm Rep* 2020;69(No. RR-#):[inclusive page numbers].

Centers for Disease Control and Prevention

Robert R. Redfield, MD, *Director*
 Anne Schuchat, MD, *Principal Deputy Director*
 Chesley L. Richards, MD, MPH, *Deputy Director for Public Health Science and Surveillance*
 Rebecca Bunnell, PhD, MEd, *Director, Office of Science*
 Arlene Greenspan, PhD, *Acting Director, Office of Science Quality, Office of Science*
 Michael F. Iademarco, MD, MPH, *Director, Center for Surveillance, Epidemiology, and Laboratory Services*

MMWR Editorial and Production Staff (Serials)

Charlotte K. Kent, PhD, MPH, <i>Editor in Chief</i>	Martha F. Boyd, <i>Lead Visual Information Specialist</i>
Christine G. Casey, MD, <i>Editor</i>	Maureen A. Leahy, Julia C. Martinroe,
Mary Dott, MD, MPH, <i>Online Editor</i>	Stephen R. Spriggs, Tong Yang,
Terisa F. Rutledge, <i>Managing Editor</i>	<i>Visual Information Specialists</i>
David C. Johnson, <i>Lead Technical Writer-Editor</i>	Quang M. Doan, MBA, Phyllis H. King,
Catherine B. Lansdowne, MS, <i>Project Editor</i>	Terraye M. Starr, Moua Yang,
	<i>Information Technology Specialists</i>

MMWR Editorial Board

Michelle E. Bonds, MBA	Timothy F. Jones, MD, <i>Chairman</i>	Patricia Quinlisk, MD, MPH
Matthew L. Boulton, MD, MPH	Katherine Lyon Daniel, PhD	Patrick L. Remington, MD, MPH
Carolyn Brooks, ScD, MA	Jonathan E. Fielding, MD, MPH, MBA	Carlos Roig, MS, MA
Jay C. Butler, MD	David W. Fleming, MD	William Schaffner, MD
Virginia A. Caine, MD	William E. Halperin, MD, DrPH, MPH	Morgan Bobb Swanson, BS
	Jewel Mullen, MD, MPH, MPA	
	Jeff Niederdeppe, PhD	

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020

Noele P. Nelson, MD, PhD¹; Mark K. Weng, MD¹; Megan G. Hofmeister, MD¹; Kelly L. Moore, MD²; Mona Doshani, MD¹; Saleem Kamili, PhD¹; Alaya Koneru, MPH¹; Penina Haber, MPH³; Liesl Hagan, MPH¹; José R. Romero, MD⁴; Sarah Schillie, MD¹; Aaron M. Harris, MD¹

¹Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; ²Department of Health Policy, Vanderbilt School of Medicine, Nashville, Tennessee; ³Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; ⁴Section of Pediatric Infectious Diseases, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Summary

Hepatitis A is a vaccine-preventable, communicable disease of the liver caused by the hepatitis A virus (HAV). The infection is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water. Hepatitis A is an acute, self-limited disease that does not result in chronic infection. HAV antibodies (immunoglobulin G [IgG] anti-HAV) produced in response to HAV infection persist for life and protect against reinfection; IgG anti-HAV produced after vaccination confer long-term immunity. This report supplants and summarizes previously published recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding the prevention of HAV infection in the United States. ACIP recommends routine vaccination of children aged 12–23 months and catch-up vaccination for children and adolescents aged 2–18 years who have not previously received hepatitis A (HepA) vaccine at any age. ACIP recommends HepA vaccination for adults at risk for HAV infection or severe disease from HAV infection and for adults requesting protection against HAV without acknowledgment of a risk factor. These recommendations also provide guidance for vaccination before travel, for postexposure prophylaxis, in settings providing services to adults, and during outbreaks.

Introduction

The hepatitis A virus (HAV) is transmitted via the fecal-oral route, usually through direct person-to-person contact or consumption of contaminated food or water (1,2). HAV infection is clinically indistinguishable from other types of acute viral hepatitis, and the illness is usually mild and self-limited when healthy persons are infected (1,2). Disease severity increases in persons who are older or immunocompromised, have chronic liver disease, or have other underlying health conditions (2–4). Infection with HAV has not been found to cause chronic infection, although prolonged or relapsing hepatitis A has been reported (5).

Recommendations for hepatitis A (HepA) vaccine were introduced incrementally in the United States. In 1996, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of children aged ≥ 2 years who lived in communities with high rates of HAV infection, for populations at increased risk for HAV infection or the adverse consequences of infection, and in outbreak settings

(6). In 1999, ACIP expanded the recommendations to include routine vaccination for the following groups: 1) children aged ≥ 2 years in 11 states (Alaska, Arizona, California, Idaho, Nevada, New Mexico, Oklahoma, Oregon, South Dakota, Utah, and Washington) with average incidence rates that were at least twice the national average during 1987–1997 (i.e., ≥ 20 cases per 100,000 population) and 2) consideration of routine vaccination of children aged ≥ 2 years in six states (Arkansas, Colorado, Missouri, Montana, Texas, and Wyoming) where average incidence rates were greater than, but less than twice, the national average (i.e., ≥ 10 but < 20 cases per 100,000 population) (7). In 2006, ACIP recommended routine HepA vaccination of all children aged 12–23 months (8). These recommendations resulted in a 95.5% decrease in reported hepatitis A cases during 1996–2011 (9). Small increases in cases occurred in 2013 and 2016 attributed to foodborne outbreaks associated with contaminated food (10,11). Beginning in 2016, greater increases in the number of reported cases occurred across the United States, primarily from widespread outbreaks of hepatitis A from person-to-person transmission (12). Low adult HepA vaccination coverage and high population susceptibility to HAV infection allow outbreaks to continue to occur (13,14). This report supplants and summarizes previously published recommendations from ACIP for the prevention of HAV infection in the United States.

Corresponding author: Noele P. Nelson, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. Telephone: 404-718-8576; E-mail: nnelson@cdc.gov.

The recommendations can be used by health care providers to update the current practice for providing HepA vaccines for preexposure and postexposure prophylaxis.

New or Updated Recommendations

The following ACIP recommendations are new, updated, or no longer recommended:

- Vaccination of all children and adolescents aged 2–18 years who have not previously received HepA vaccine (i.e., children and adolescents are recommended for catch-up vaccination)
- Vaccination of all persons aged ≥ 1 year infected with human immunodeficiency virus (HIV)
- Vaccination of persons with chronic liver disease, including but not limited to persons with hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, or an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level persistently greater than twice the upper limit of normal
- Vaccination of pregnant women who are identified to be at risk for HAV infection during pregnancy (e.g., international travelers, persons who use injection or noninjection drugs [i.e., all those who use illegal drugs], persons who have occupational risk for infection, persons who anticipate close personal contact with an international adoptee, or persons experiencing homelessness) or for having a severe outcome from HAV infection (e.g., persons with chronic liver disease or persons with HIV infection)
- Vaccination during hepatitis A outbreaks of persons aged ≥ 1 year who are at risk for HAV infection (e.g., persons who use injection or noninjection drugs [i.e., all those who use illegal drugs], persons experiencing homelessness, or MSM) or who are at risk for severe disease from HAV (e.g., persons with chronic liver disease or who are infected with HIV)
- Vaccination in settings providing services to adults in which a high proportion of persons have risk factors for HAV infection (e.g., health care settings with a focus on those who use injection or noninjection drugs [i.e., all those who use illegal drugs], group homes, and nonresidential day care facilities for developmentally disabled persons)
- Vaccination of persons who receive blood products for clotting disorders (e.g., hemophilia) is no longer recommended.

New CDC clinical guidance is provided for the vaccination of the following: infants aged 6–11 months traveling outside the United States, persons aged >40 years, persons with immunocompromising conditions, and persons with chronic

liver disease planning on traveling, persons with HIV infection, pregnant women, postexposure prophylaxis and vaccination during outbreaks.

Methods

ACIP's Hepatitis Vaccines Work Group comprises professionals from academic medicine (pediatrics, family medicine, internal medicine, infectious diseases, occupational health, and preventive medicine), federal and state public health agencies, and medical societies. The work group considered previously published ACIP HepA vaccine recommendations, reviewed the epidemiology of and literature for hepatitis A, directed an economic analysis, and deliberated over the recommendations.

This report supplants and summarizes previously published ACIP recommendations for HepA vaccination of children and adults (8,15–17). Data used for general clarifications to the recommendations were summarized based on findings from literature searches that were completed on March 19, 2019, and updated before publication. The literature searches included clinical trials and comparative studies conducted worldwide and published in English since 2005. Epidemiologic and vaccination coverage data were reviewed. All studies yielding pertinent information were deemed relevant for inclusion. The work group organized, evaluated, and discussed information to create the recommendations using the Evidence to Recommendation (EtR) Framework (<https://www.cdc.gov/vaccines/acip/recs/grade/etr.html>) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) (<https://www.cdc.gov/vaccines/acip/recs/grade/table-refs.html>).

The EtR framework was used to review and evaluate data on HepA catch-up vaccination for children and adolescents aged 2–18 years. GRADE was not used to evaluate the evidence for HepA catch-up for several reasons: 1) HepA vaccine has been recommended for administration to children since 1996, 2) HepA vaccine has been recommended for catch-up vaccination based on shared clinical decision-making since 2006, and 3) the efficacy and safety of HepA vaccines has been evaluated and well-documented since 1996 (see Vaccine Safety). The EtR framework tables for HepA catch-up vaccination are available on the ACIP website (<https://www.cdc.gov/vaccines/acip/recs/grade/hep-a-catchup-etr.html>).

GRADE was performed and the EtR framework was used to review and evaluate data on persons with HIV infection as a risk group for HepA vaccination, and the findings were presented to ACIP at the February and June 2019 meetings. Details on the methods used for GRADE, including the search protocol, databases searched, inclusion criteria, a summary of

the evidence, the grading of the evidence, and information on the additional factors considered are provided on the ACIP website (<https://www.cdc.gov/vaccines/acip/recs/grade/hep-a-hiv.html>), as are the EtR framework tables (<https://www.cdc.gov/vaccines/acip/recs/grade/hep-a-hiv-etr.html>).

To assess vaccine safety, two post-licensure surveillance systems were searched for adverse events during 2005–2018. The Vaccine Adverse Events Reporting System (VAERS) (<https://www.vaers.hhs.gov>) is a national passive surveillance system, whereas the Vaccine Safety Datalink (<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd>) contains population-based vaccine safety studies. Vaccine safety hypotheses can be generated, but not assessed, through VAERS and are subject to limitations including reporting biases and inconsistent data quality (18,19). The Vaccine Safety Datalink can be used to assess hypotheses that arise from reviews of medical literature, reports to VAERS, changes in vaccination schedules, or the introduction of new vaccines (20) (see Vaccine Safety).

During May 2014–June 2019, the work group held 31 teleconferences focused on HepA vaccine topics. Work group and ACIP members also reviewed and commented on a draft of the statement in its entirety before ACIP's June 2019 meeting. A summary of work group discussions was presented to ACIP on June 27, 2019. At that time, ACIP members voted to approve a draft of the HepA vaccine recommendations, including the recommendation that all children and adolescents aged 2–18 years who have not previously received HepA vaccine be vaccinated (i.e., children and adolescents are recommended for catch-up vaccination) and that all persons with HIV infection aged ≥ 1 year be vaccinated with HepA vaccine. The ACIP statement was modified during the subsequent review process at CDC to update and clarify wording in the report; however, substantive changes were made only to the clinical guidance on revaccination for persons with HIV, based on ACIP committee deliberations during the June 2019 meeting.

HAV Background


Hepatitis A Vaccine Coverage

Among children born during 2015–2016, coverage with ≥ 2 doses of the HepA vaccine by age 35 months was 76.6% and with ≥ 1 dose by age 24 months was 84.7% (21). In 2017, coverage with ≥ 2 doses among adolescents aged 13–17 years was 68.4% and with 1 dose was 77.2% (CDC, unpublished data, 2019). In 2017, coverage with ≥ 2 doses among adults aged ≥ 19 years was 10.9% overall, with 17.7% coverage among travelers and 20.8% coverage among persons with chronic liver disease (14).

Epidemiology

Preliminary data indicate that in 2018, approximately 12,500 cases of hepatitis A were reported to CDC from 50 states and the District of Columbia (CDC, unpublished data, 2020), representing a substantial increase from 2017 due to widespread outbreaks of hepatitis A from person-to-person transmission (12). In 2017, a total of 3,366 cases of hepatitis A were reported to CDC (Figure 1) (9). The overall incidence rate of reported cases in 2017 was one case per 100,000 population (9). After adjusting for under-ascertainment and underreporting, an estimated 6,700 hepatitis A cases (95% confidence interval [CI]: 4,700–7,400) occurred in 2017 (9).

FIGURE 1. Number of reported and estimated hepatitis A cases — United States, 2013–2017



Source: CDC, National Notifiable Diseases Surveillance System. Surveillance for viral hepatitis—United States, 2017. Atlanta, GA: CDC, US Department of Health and Human Services. <https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm>

Rates of reported hepatitis A reached a nadir in 2014 for all age groups except those aged 10–19 years, for whom the nadir occurred in 2015. Rates increased in 2016 and 2017 among adults as a result of large community hepatitis A outbreaks with person-to-person transmission among persons who used drugs and persons experiencing homelessness (9,12,22). HAV infections during 2016–2017 also increased among men who have sex with men (MSM) (23) and, to a much lesser extent, in association with consumption of imported HAV-contaminated food (11).

In 2017, adults aged 30–39 years had the highest hepatitis A rate of all age groups (2.1 cases per 100,000 population), and children aged ≤9 years had the lowest rate (0.1 cases per 100,000 population) (9). Rates of HAV infection remain low in children and adolescents because of routine childhood HepA vaccination (9). However, rates of HAV infection were higher among adults compared with children and adolescents because of low adult vaccine coverage (14) and higher HAV susceptibility (13). Among U.S.-born adults aged ≥20 years, HAV susceptibility prevalence (total antibody to HAV negative) was 74.1% (95% CI: 72.9%–75.3%) during 2007–2016 (13).

The reported rates of HAV infection among males and females have been similar since 2003 when the rates were 2.82 cases per 100,000 population for males and 2.43 for females (9). The rates decreased over time consistent with the national trend and remained similar; however, from 2016 to 2017, rates increased more markedly for males (0.7 cases per 100,000 population in 2016 to 1.38 in 2017) than for females (0.55 cases per 100,000 population in 2016 to 0.7 cases in 2017), consistent with higher rates of drug use among men compared with women (9,24). In 2017, the rates of reported hepatitis A cases were similar among all racial/ethnic populations. The highest rate was among white, non-Hispanics (0.98 per 100,000 population), and the lowest was among American Indians/Alaska Natives (0.48 per 100,000 population) (9).

Virus Description

HAV has a single-stranded, positive-sense RNA genome that is approximately 7.5 kb long. The virus is a member of the *Picornaviridae* family in the *Hepatovirus* genus (25–28). Two forms of infectious virions exist (29). A naked, nonenveloped virion 27 nm in diameter is shed in the feces of infected persons, and a quasi-enveloped virion is found in the blood of infected persons and secreted nonlytically from infected cells (29).

HAV is classified into six genotypes. Genotypes I, II, and III circulate among humans, whereas genotypes IV, V, and

VI infect simians (30,31). The antibody response to HepA vaccines is similar across genotypes (32). Only one human HAV serotype has been identified globally (30).

Transmission

HAV is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water (33). Children were a key source of HAV transmission before HepA vaccination was available and recommended routinely for children because the majority of children infected with HAV have asymptomatic or unrecognized infections and can shed the virus in their feces for months (34,35). Transmission currently occurs primarily among susceptible adults.

Common-source outbreaks and sporadic cases also occur from exposure to food or water with fecal contamination. Uncooked foods have been recognized as a source of outbreaks (36). Cooked foods also can transmit HAV if the heat level used in preparation is inadequate to inactivate the virus or if food is contaminated after cooking, which can occur during outbreaks associated with infected food handlers (36). Waterborne outbreaks of hepatitis A are infrequent in developed countries with well-maintained sanitation and water supplies (37). Depending on conditions, HAV can be stable in the environment for months (33,38). HAV also is stable when frozen (10,39–41). Heating foods at temperatures >185°F (>85°C) for 1 minute or disinfecting surfaces with a 1:100 dilution of sodium hypochlorite (i.e., household bleach) in tap water inactivates HAV (42).

On rare occasions, HAV has been transmitted by transfusion of blood or blood products collected from donors during the viremic phase of their infection (43,44). Since 2002, nucleic acid amplification tests (NAATs) for the detection of HAV RNA have been applied to the screening of source plasma used for the manufacture of plasma-derived products, drastically reducing the transmission risk from plasma-derived products (45).

In experimentally infected nonhuman primates, HAV has been detected in saliva during the incubation period (46), as well as in serum and stool samples. HAV also has been detected in human saliva (47,48); however, no studies assessing the transmission of HAV infection by saliva are available.

Clinical Features and Natural History

Infection in humans occurs after an average incubation period of 28 days (range: 15–50 days) (49,50). Symptomatic HAV infection is clinically indistinguishable from other types of acute viral hepatitis but is usually mild and self-limited, with an abrupt onset that can include fever, malaise, anorexia, nausea, and abdominal discomfort, followed within a few days to a week by

dark urine, pale stools, and jaundice (1). The likelihood of having symptoms with HAV infection is related to age. In children aged <6 years, 70% of infections are asymptomatic; illnesses that do occur are not typically accompanied by jaundice (1,51). Among older children and adults, infection typically is symptomatic, with jaundice occurring in >70% of patients (1,52). Signs and symptoms usually resolve within 2–3 months, with complete recovery within 6 months (53). However, 10%–15% of symptomatic persons have prolonged or relapsing hepatitis A lasting up to 6 months and should be considered infectious (5). Although relapse consists of elevated liver enzyme levels and detection of virus in stools, recovery from relapse is universal (52–54), and infection with HAV has not been found to cause chronic infection. Fulminant hepatic failure is rare and occurs in <1% of cases (2), although hepatic failure has been observed in a higher percentage of cases in the widespread outbreaks that began in 2016 (12,55).

In infected persons, HAV replicates in the liver, is excreted in bile, and is shed in stool. Peak transmissibility in infected persons occurs during the 2-week period before the onset of jaundice or elevation of liver enzymes, when concentration of virus in stool is highest (33). The concentration of virus in the stool decreases after jaundice appears, and most persons cease to be infectious 1 week after jaundice onset (33). Children can shed HAV for longer periods than adults, up to 10 weeks (56) after onset of clinical illness. In one nosocomial outbreak, infants who were infected as neonates shed HAV for up to 6 months (57). Chronic shedding of HAV in feces does not occur typically; however, recurrent shedding occurs during relapses in persons with relapsing illness (54). Viremia occurs soon after infection and persists through the period of liver enzyme elevation but at concentrations several orders of magnitude lower than in stool (43,56–58). Prolonged viremia and fecal shedding of HAV for more than a month in immunocompetent persons and for more than a year in immunocompromised patients has been reported in several studies (59,60). Prolonged viremia after organ transplantation also has been described (61).

Interpretation of Serologic Markers and Diagnosis of HAV Infection


Hepatitis A cannot be differentiated from other types of viral hepatitis on the basis of clinical or epidemiologic features alone. Diagnosis of HAV infection requires the detection of either immunoglobulin M (IgM) anti-HAV in serum or HAV RNA in serum or stool. IgM anti-HAV, a marker of acute illness, becomes detectable within 5–10 days of the onset of symptoms in the majority of persons (58,62), usually peaks within 1 month of illness, and decreases to undetectable levels within

6 months after infection (58,62–64) (Figure 2). However, positive tests for IgM anti-HAV in persons >1 year after infection have been reported, as have likely false-positive tests in persons without evidence of recent HAV infection (65–67). Therefore, to reduce false-positive tests, persons should only be tested for IgM anti-HAV if they are symptomatic and suspected of having HAV infection (66–68). Total anti-HAV or immunoglobulin G (IgG) anti-HAV testing is used in epidemiologic studies to measure the prevalence of previous infection or clinically to determine whether a person with an indication for preexposure prophylaxis is already immune. IgG anti-HAV is produced either in response to natural infection or after vaccination with HepA vaccine, appearing early in the course of infection, remaining detectable for the person's lifetime, and providing lifelong protection against the disease (69–71). The antibody test for total anti-HAV measures both IgG anti-HAV and IgM anti-HAV. Although assays for the detection of IgG anti-HAV are available, in the absence of an IgG anti-HAV test, a total anti-HAV–positive sample from a symptomatic person should be subsequently tested for IgM anti-HAV to establish the acute stage of HAV infection (72). Persons who test positive from a total anti-HAV test and negative from an IgM anti-HAV test are considered immune, either from past infection or vaccination.

Biochemical evidence of hepatitis includes elevated levels of serum bilirubin and serum hepatic enzymes, including ALT, AST, alkaline phosphatase, and gamma-glutamyltranspeptidase. Elevations in AST and ALT levels usually occur 5–10 days before symptom onset. Serum bilirubin and aminotransferase levels usually return to normal by 2–3 months after illness onset (53).

Molecular epidemiologic technologies, when applied in combination with conventional epidemiologic methods, have been useful in investigating outbreaks and determining transmission links (32). The detection and sequencing of HAV RNA from water, food, and blood or stool of infected persons provide important information for tracing and characterizing HAV strains and identifying the source of water and foodborne hepatitis A outbreaks. HAV RNA can be detected using NAAT technologies in the blood and stool of the majority of persons during the acute phase of infection using NAAT technologies (73–75). HAV RNA in liver biopsies, cell cultures, or environmental samples can also be detected using various NAAT-based research methodologies (76). Growth of HAV in cell culture requires a long adaptation period and is associated with acquisition of various adaptive mutations in the viral genome (77,78). However, detection of serologic markers is sufficient for routine surveillance.

FIGURE 2. Immunologic and clinical events associated with hepatitis A virus infection and recovery



Source: CDC. Diagnosis and management of foodborne illnesses. MMWR Recomm Rep 2004;53(No. RR-4).

Abbreviations: ALT = alanine aminotransferase; HAV = hepatitis A virus; IgG = immunoglobulin G; IgM = immunoglobulin M.

Adults at Risk for HAV Infection or for Severe Disease from HAV

International Travelers


Unvaccinated persons from developed countries who travel to countries that have high or intermediate hepatitis A endemicity have a substantial risk for acquiring hepatitis A (9,79). Endemicity is related to the age at midpoint of population immunity (AMPI) (Figure 3); as the AMPI increases, the endemicity level of hepatitis A generally decreases (80). However, determining global HAV endemicity is complex, and limited data are available on subpopulation variation of anti-HAV seroprevalence within regions (80,81). Travelers at risk include tourists, nonimmune immigrants and their children returning to their country of origin to visit friends or relatives, military personnel, missionaries, and others who work or study abroad. Hepatitis A remains one of the most common vaccine-preventable diseases acquired during travel (82). Risk is highest for those who live in or visit rural areas, trek in backcountry areas, or frequently eat or drink in

settings with poor sanitation. However, cases of travel-related hepatitis A can occur in travelers who have tourist itineraries, accommodations, and eating behaviors that are considered low risk. Travelers who acquire hepatitis A during their trips might transmit HAV to others on their return.

Men Who Have Sex with Men

Hepatitis A outbreaks among MSM have been reported frequently (83,84). Since 2016, multiple hepatitis A outbreaks have been reported among MSM linked to travel in areas with ongoing HAV transmission among MSM (e.g., in >20 European Union countries) (23,85–91). Molecular epidemiology shows similar HAV strains circulating among HAV-infected MSM, suggesting transmission chains occur in this population (74). ACIP has recommended routine HepA vaccination of MSM since 1996 (6). Despite this longstanding recommendation, vaccination coverage among MSM remains suboptimal, with vaccination coverage estimated at 25%–45% overall (13,92–94), although vaccination coverage might be higher in targeted high-risk settings (95).

FIGURE 3. Estimated age at midpoint of population immunity* to hepatitis A, by country — 2015



Source: Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus. *Cold Spring Harb Perspect Med* 2018;8:a031716.

Abbreviations: AMPI = age at midpoint of population immunity; HAV = hepatitis A virus.

* The AMPI is the youngest age at which half of the birth cohort has serologic evidence of previous exposure to HAV. As the AMPI increases (light to dark), the endemicity level of hepatitis A generally decreases.

Persons Who Use Injection or Noninjection Drugs

Outbreaks occur frequently among persons who use injection or noninjection drugs (i.e., all those who use illegal drugs) (12,55,96–98). Transmission among persons who use injection or noninjection drugs occurs via the fecal-oral route (resulting from poor hygiene practices or lack of adequate sanitation) and also might occur via the percutaneous route among persons who inject drugs (96,98); however, HAV RNA levels are several log₁₀ units lower in serum than in feces. Since 1996, ACIP has recommended HepA vaccination for persons who use injection or noninjection drugs (6). Despite this longstanding recommendation, HAV seropositivity remains low (20%–40%) in this population (13,99,100).

Persons with Occupational Risk for Exposure

Outbreaks of hepatitis A have been reported among persons working with nonhuman primates, including Old World and New World species (101,102). Primates that were infected had been born in the wild (103). Persons working with clinical or nonclinical material containing HAV in a research laboratory setting are considered at risk for HAV infection.

Health care personnel are not at substantially increased risk for HAV infection through occupational exposure, and health care–associated HAV transmission is rare (see Groups and Settings with Low Risk for Hepatitis A) (104). Food handlers

are also not considered at increased risk for HAV infection (see Groups and Settings with Low Risk for Hepatitis A) (36).

Persons Who Anticipate Close Personal Contact with an International Adoptee

HAV infection can occur among family members of international adoptees (e.g., have close personal contact) (16,105). The majority of children adopted from foreign countries by families in the United States come from countries where hepatitis A is of high or intermediate endemicity, which is related to the AMPI; as the AMPI increases, the endemicity level of hepatitis A generally decreases (Figure 3) (80). Approximately 50 cases of HAV infection have been reported after exposure to international adoptees (16,106–110), likely an underestimate because data regarding contact with an international adoptee is not routinely collected as part of national hepatitis A surveillance. The risk for HAV infection among close personal contacts of international adoptees was estimated at 106 per 100,000 household contacts of international adoptees within the first 60 days of their arrival in the United States (CDC, unpublished data, 2009). By comparison, according to surveillance data, the estimated rate of symptomatic hepatitis A in the U.S. general population in 2009 was 0.6 cases per 100,000 population (111).

Persons Experiencing Homelessness

A homeless person is defined as 1) a person who lacks housing (regardless of whether the person is a member of a family), including a person whose primary residence during the night is a supervised public or private facility (e.g., shelter) that provides temporary living accommodations and a person who is a resident in transitional housing, 2) a person without permanent housing who might live on the streets; or stay in a shelter, mission, single-room occupancy facility, abandoned building, vehicle, or any other unstable or nonpermanent situation, or 3) who is “doubled up,” a term that refers to a situation where persons are unable to maintain their housing situation and are forced to stay with a series of friends or extended family members. In addition, previously homeless persons who are to be released from a prison or a hospital might be considered homeless if they do not have a stable housing situation to which they can return. A recognition of the instability of a person’s living arrangements is critical to the definition of homelessness (112–114).

In 2017, outbreaks caused by person-to-person HAV transmission among persons experiencing homelessness signaled a shift in hepatitis A epidemiology in the United States (12). Persons experiencing homelessness might have difficulty implementing recommended nonvaccine strategies to protect themselves from exposure (e.g., access to clean toilet facilities, regular handwashing, and avoidance of crowded living conditions). For this reason, vaccination is the most reliable protection from HAV infection for persons experiencing homelessness. HepA vaccination of persons experiencing homelessness provides individual protection and increases herd immunity, reducing the risk for large-scale outbreaks from person-to-person transmission in this population (15). In addition, homelessness is associated with other known risk behaviors for HAV infection (e.g., drug use) (115).

Persons with HIV Infection

Data suggest that up to 87% of persons with HIV infection are susceptible (i.e., have negative total or IgG anti-HAV test results) to HAV infection because of lack of previous HAV infection, lack of receipt of HepA vaccination, or poor response to HepA vaccination (116–122). Persons with HIV infection who have underlying liver disease are at increased risk for severe disease from HAV infection (123,124). HAV infection in persons with HIV infection is prolonged and might increase HIV replication, potentially increasing HIV transmission, and can lengthen the HAV transmission period (124–132). Protracted hepatitis A outbreaks can occur among persons with

HIV infection (133,134) because HAV viremia in these persons tends to be elevated and the hepatitis A clinical course tends to be prolonged compared with HIV-uninfected persons (131), resulting in a higher risk for HAV transmission (131,133).

HepA vaccine seroconversion rates (i.e., achieving IgG anti-HAV levels after vaccination that are higher than the correlate of protection as determined by the study) in persons with HIV infection range from 50% to 94% (135,136) (see Correlate of Protection). HepA vaccine does not increase HIV viral load, affect CD4 cell count, or accelerate progression to acquired immunodeficiency syndrome (AIDS) (137–142). Protection against HAV in persons with HIV infection can be achieved, despite lower seroconversion rates compared with HIV-negative persons (see Vaccine-Induced Seroprotection) (136,143,144). In one study among 130 persons with HIV infection, 85% maintained seropositivity 6–10 years after a 2-dose vaccine series (145). Vaccination at higher CD4 counts is associated with better vaccine-induced immune responses (135,136,141,145–147).

Persons with Chronic Liver Disease

Persons with chronic liver disease are not at increased risk for acquiring HAV infection. However, concurrent underlying chronic liver disease (e.g., HBV infection, HCV infection, cirrhosis, fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) has been associated with increased risk for fulminant hepatitis when HAV infection occurs (3,148–152). Among patients hospitalized for HAV infection in the United States during 2010–2011, the percentage hospitalized with any liver disease (e.g., other viral hepatitis, non-alcohol-related cirrhotic liver disease, alcohol-related liver disease, liver disease not otherwise specified, and biliary tract disease) was high (38.3%; 2.7 per 100,000 population) (153).

Persons Living in Group Settings for Those with Developmental Disabilities

Historically, HAV infection was highly endemic in institutions for persons with developmental disabilities (154). Because fewer children with developmental disabilities have been institutionalized and as conditions in institutions have improved, the incidence and prevalence of HAV infection in these settings have decreased (8). Persons with developmental disabilities who require assistance with activities of daily living often live in group homes or small residential facilities. Outbreaks have occurred in these settings and are associated with poor hand hygiene, wearing diapers, and living in close quarters (155,156).

Persons Who Are Incarcerated

Persons with a history of using drugs or homelessness are overrepresented in correctional facilities and often cycle frequently between correctional facilities and the community (157,158). Ongoing drug use within incarcerated populations, congregate and sometimes overcrowded living conditions, and shared hygiene facilities can increase HAV transmission within jails and prisons (157).

Offering HepA vaccine in jails and prisons is an effective strategy to reach persons at high risk for HAV infection who are otherwise difficult to access in the community. Corrections-based vaccination programs have played a role in mitigating communitywide outbreaks of hepatitis A in the United States, the United Kingdom, and Australia (96,159,160). These programs also have been successfully implemented to limit HAV transmission inside jails and prisons (159,160). Observational data suggest that partnerships with correctional staff and intensive education efforts can lead to >90% uptake of the first dose of a Twinrix (combined HepA and hepatitis B [HepB] vaccine) series within correctional facilities (161,162). Accelerated dosing schedules also have been used to increase the likelihood that multiple doses of a Twinrix vaccine series are administered before release from short-term incarceration (163).

Older Adults (Aged >40 Yrs)

HAV infections are usually symptomatic among adults. The severity of hepatitis A disease increases with age (1). Adults aged >40 years are more likely to be hospitalized after HAV infection (153).

Groups and Settings with Low Risk for Hepatitis A

Persons with Blood Clotting Disorders

Persons who receive blood products for clotting disorders (e.g., hemophilia) are no longer specifically recommended to receive HepA vaccine. Such persons were first recommended to receive HepA vaccination in 1996 (6). Previously, some viral inactivation processes focused only on treatment of blood products with solvents and detergents, which inactivated lipid-enveloped viruses (164) but not nonenveloped viruses such as HAV, resulting in a risk for infection (165). Secondary virus reduction steps are now common and have closed this gap (166–168). In addition, in the United States, >80% of persons with clotting disorders receive recombinant clotting factor concentrates, which are sterilized (e.g., pasteurization, heat inactivation, and filtration), eliminating the risk for HAV contamination (168). The risk for HAV transmission via transfusion of blood products among persons with clotting

disorders is now considered the same as that among the general population (168), and source plasma is now screened for HAV (167).

Food Service Establishments and Food Handlers

HepA vaccination is not specifically recommended for persons who handle food in the absence of other risk factors. Foodborne hepatitis A outbreaks occur relatively infrequently in the United States; however, recent outbreaks of hepatitis A related to pomegranate arils (the fruit-coated seeds) imported from Turkey, frozen scallops imported from the Philippines, and frozen strawberries imported from Egypt demonstrated the risk for outbreaks related to foods imported from HAV-endemic areas (10,11,169). Contamination of food with HAV can happen at any point: growing, harvesting, processing, handling, or after cooking. Food handlers are not at increased risk for hepatitis A because of their occupation (36). Transmission of HAV from infected food handlers to susceptible consumers or restaurant patrons in the workplace is rare (36,170,171). Transmission among food handlers has not been common since the adoption of the universal childhood HepA vaccination recommendation in 2006, despite costly and resource-intensive investigations of HAV infections among food handlers. One study found that in >90% of case investigations of infected food handlers, only the food handler was infected, with no secondary cases (172). A survey of state health departments experiencing person-to-person hepatitis A outbreaks during 2016–2019 demonstrated that among almost 23,000 hepatitis A outbreak cases reported from states, <4% occurred among food handlers; secondary infections among patrons accounted for 0.2% of outbreak cases (173). The risk for secondary infection from hepatitis A–infected food handlers to food establishment patrons in these person-to-person hepatitis A outbreaks was <1% (173).

Child Care Centers

In the past, hepatitis A outbreaks occurred among children attending child care centers and employees of those centers; however, the outbreak frequency decreased following widespread adoption of universal childhood vaccination (9,51,174). Hepatitis A outbreaks in child care centers are now rare. Historically, poor hygiene among children who wore diapers and the staff who handled and changed diapers contributed to the spread of HAV infection in child care centers; outbreaks rarely occurred in child care centers in which care was provided only to children who were toilet trained (51,174). Because HAV infection among young children is typically mild or asymptomatic, child care center outbreaks were often only identified when adult contacts (typically parents) became ill (51,174).

Schools

HepA vaccination is recommended for all children. Before universal childhood vaccination, the occurrence of hepatitis A cases in U.S. elementary or secondary schools typically reflected disease acquisition in the community, and HAV transmission in school settings was uncommon (and remains uncommon). If multiple cases occur among children at a school, a common source of infection should be investigated (39,75).

Health Care Institutions

HepA vaccine is not routinely recommended for health care personnel. Health care personnel are all paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air (175). These personnel include but are not limited to emergency medical service personnel, nurses, nursing assistants, physicians, technicians, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the health care facility, and persons in departments not directly involved in patient care but who could be exposed to infectious agents that can be transmitted in the health care setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer) (<https://www.cdc.gov/infectioncontrol/pdf/guidelines/infection-control-HCP-H.pdf>) (175).

Health care–associated HAV transmission is rare. In the past, outbreaks were observed in neonatal intensive care units when infants acquired infections from transfused blood and subsequently transmitted HAV to other infants and staff (57,176,177). Health care personnel are not at substantially increased risk for HAV infection through occupational exposure (104). Outbreaks of hepatitis A caused by transmission from adult patients to health care personnel have typically been associated with fecal incontinence and inadequate hand hygiene (61,178). However, the majority of hospitalized patients who have hepatitis A are admitted after onset of jaundice, when they are beyond the point of peak infectivity (179,180). Health care personnel should be encouraged to adhere to recommended infection control practices, standard precautions, and contact precautions for incontinent patients, including hand hygiene (181).

Workers Exposed to Sewage

HepA vaccination is not routinely recommended for persons handling untreated sewage. Data from serologic studies

conducted outside the United States indicate that workers who had been exposed to sewage had a possible elevated risk for HAV infection; however, these analyses did not control for other risk factors (e.g., age or travel to endemic areas) (182–184). Published reports of three serologic surveys conducted among U.S. wastewater workers and appropriate comparison populations did not identify any substantial or consistent increase in the prevalence of anti-HAV among wastewater workers (185–187). In addition, in the United States, floods, which can carry raw sewage, are unlikely to cause outbreaks of communicable diseases, and outbreaks of HAV caused by flooding have not been reported (36,188).

Public Water Systems

Hepatitis A outbreaks have previously been reported among persons using private or community wells, swimming pools, or public drinking water contaminated by sewage from nearby septic systems (36,37,189–194). Water treatment processes and dilution within public water systems render HAV noninfectious (36). No hepatitis A outbreaks associated with drinking water have been reported since 2009 in the United States (37). Recreational water venues (e.g., spas and swimming pools) that are adequately treated and are not contaminated (e.g., by sewage or children in diapers) are unlikely to pose a risk for hepatitis A outbreaks (36,192).

Outbreaks

Most cases of hepatitis A in the United States result from person-to-person transmission during communitywide outbreaks (195,196). Since 2016, communitywide outbreaks have occurred predominantly among adults with specific risk factors (e.g., persons who use drugs, persons experiencing homelessness, and MSM) (12). However, common-source outbreaks from contaminated food occur as well. Foods that have been implicated in multiple hepatitis A outbreaks (e.g., lettuce, green onions, strawberries, raspberries, and pomegranate arils) have typically been eaten raw (10,39,169,197–200). For example, a large outbreak (approximately 600 infected) at a single restaurant was associated with imported green onions (199,200). Shellfish-associated outbreaks have occurred after consumption of raw or partially cooked oysters, clams, scallops, or mussels harvested from contaminated waters (11,201). Contaminated food outbreaks continue to occur and remain a risk (e.g., a multistate outbreak linked to frozen strawberries and a Hawaii outbreak linked to frozen scallops eaten raw, both occurring in 2016) (11,169).

Prophylaxis Against HAV Infection

Hepatitis A Vaccines

Vaccines containing HAV antigen that are licensed in the United States are the single-antigen vaccines Havrix and Vaqta and the combination vaccine Twinrix (containing both HAV and HBV antigens). All are inactivated vaccines. The three vaccines were licensed by the U.S. Food and Drug Administration (FDA): Havrix in 1995, Vaqta in 1996, and Twinrix in 2001 (202).

Preparation

Inactivated HepA vaccines are prepared using methods similar to those used for inactivated poliovirus vaccine (203,204). HepA vaccines contain an aluminum adjuvant. Havrix and Twinrix contain 2-phenoxyethanol as a preservative, and Vaqta is formulated without a preservative. None of the HepA vaccines licensed in the United State contain thimerosal as a preservative. For Havrix and Twinrix the final vaccine potency (per dose) is expressed as enzyme-linked immunosorbent assay (ELISA) units of HAV antigen. The antigen content for Vaqta is expressed as units of HAV antigen. The manufacturer package inserts include additional information on HepA vaccine preparation (202).

Vaccine Storage and Shipment

HepA vaccine should be stored and shipped at temperatures ranging from 36°F to 46°F (2°C to 8°C) and should not be frozen (205). The manufacturer package inserts include additional information (202).

Route of Administration

The vaccine should be administered intramuscularly into the anterolateral aspect of the thigh or the deltoid muscle of the upper arm, depending on the person's age (205). A needle length appropriate for the person's age and size should be used (205). When HepA vaccines are administered concomitantly with other vaccines or immune globulin (IG), they should be administered in a different anatomic site (e.g., separate limbs) (205). If HepA vaccine was administered subcutaneously, inadvertently or for a clinical reason, the dose is considered valid and does not need to be repeated (205–207).

Vaccination Schedule and Dosage

Vaqta

Vaqta is licensed in two formulations. Persons aged 12 months through 18 years should receive 25 units of HAV

antigen per dose in a 2-dose schedule; persons aged ≥19 years should receive 50 units per dose in a 2-dose schedule (Table 1).

Havrix

Havrix also is licensed in two formulations. Persons aged 12 months through 18 years should receive 720 ELISA units per dose in a 2-dose schedule; persons aged ≥19 years should receive 1,440 ELISA units per dose in a 2-dose schedule (Table 1).*

Twinrix

Twinrix is licensed for use in adults aged ≥18 years. Twinrix contains 720 ELISA units of HAV antigen (half of the Havrix adult dose) and 20 µg of recombinant HBV surface antigen protein (the same as the Engerix-B adult dose) (Table 1). Primary vaccination with Twinrix consists of 3 doses, administered on a 0-, 1-, and 6-month schedule, the same schedule as is commonly used for single-antigen HepB vaccine. After 3 doses of Twinrix, antibody responses to both HAV antigen and HBV surface antigens are equivalent to responses seen after the single-antigen vaccines are administered separately on standard schedules (208,209); additional information is available in the Twinrix package insert (202). Twinrix may be administered before travel or any other potential exposure on an accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months that provides long-term protection (202).

Booster and Challenge Doses

A HepA vaccine dose may be used to determine the presence of vaccine-induced immunologic memory through generation of an anamnestic response. The term “booster dose” or “challenge dose” has been used to refer to a dose of HepA vaccine administered after a primary vaccination series to provide rapid protective immunity against substantial infection (i.e., infection resulting in serologic test results positive for HAV, clinically significant disease, or both).

Vaccine Performance

Detection of Anti-HAV after Vaccination

Correlate of protection. The correlate of protection is defined as an immune response (i.e., IgG anti-HAV titer) that is responsible for and statistically interrelated with protection (210). Anti-HAV levels are measured in comparison with a World Health Organization reference IG reagent and are expressed as milli-international units per milliliter (mIU/mL). Seroconversion (response to vaccination) is defined as achieving a detectable and quantifiable postvaccination IgG anti-HAV level of ≥10 mIU/mL

* A third pediatric formulation of Havrix of 360 ELISA units per dose administered in a 3-dose schedule was recommended for persons aged 2–18 years in 1996 (6,202); however, by 1999 the pediatric formulation of 360 ELISA units per dose was no longer available and was no longer recommended (7).

by standard assays (210,211). Seroprotection is considered a surrogate of clinical protection and persists when IgG anti-HAV levels remain higher than the correlate of protection.

The absolute lower limit of anti-HAV needed to prevent HAV infection has not been determined, although the limit is likely quite low because IG provides about 90% efficacy in preventing hepatitis A, and very low levels of anti-HAV are detected in IG recipients (212,213). The concentrations of anti-HAV achieved after passive transfer by IG or active induction by vaccination are tenfold to 100-fold lower than those produced in response to natural infection (63). Clinical studies have yielded limited data from which a minimum protective antibody level can be derived because vaccine-induced levels of antibody are usually high and few infections have been detected among vaccinated persons (i.e., vaccine failure). Antibody levels of 10–33 mIU/mL using different assays have been proposed as the threshold for protection from HAV infection in humans (214), although one study proposed that any detectable level of IgG anti-HAV might suggest protection (72). Because no absolute protective level has been defined, the lower limit of detection of the particular assay being used has typically been considered the protective level; postvaccination studies use ≥10 mIU/mL as the minimum protective level (210,211,215).

IgM anti-HAV after vaccination. HepA vaccination can induce detectable IgM anti-HAV, particularly if the test is

conducted within a few weeks after vaccination. IgM anti-HAV has been detected 2–3 weeks after administration of 1 dose of vaccine in 8%–20% of adults (216) (CDC, unpublished data, 1995). To reduce false-positive tests, persons should only be tested for IgM anti-HAV if they are symptomatic and suspected of having HAV infection (66–68).

Immune Globulin

IG provides protection against hepatitis A through passive transfer of antibody. GamaSTAN is a sterile, preservative-free solution of IG for intramuscular administration and is used for prophylaxis against diseases caused by HAV, measles, varicella, and rubella viruses (see GamaSTAN package insert) (217). GamaSTAN is the only IG product approved by FDA for hepatitis A prophylaxis. In 2017, the dosing of IG was changed to reflect decreased IgG anti-HAV potency (218,219), likely resulting from decreasing prevalence of previous HAV infection among plasma donors (Table 2). GamaSTAN can be administered simultaneously with inactivated vaccines or toxoids in a different anatomic site (e.g., separate limbs) or at any time interval between doses (205).

However, the effect of IG preparations on the response to certain live-virus vaccines is unknown, and antibodies in GamaSTAN might interfere with live-virus vaccines such as measles, mumps, and rubella (MMR) vaccine and varicella vaccine (205). When MMR and varicella vaccines are

TABLE 1. Vaccines used to prevent hepatitis A virus infection

Vaccine	Trade name (manufacturer)	Age group (yrs)	Dosage	Route	Schedule	Booster
HepA, inactivated (2 doses)	Havrix (GlaxoSmithKline)	1–18	0.5 mL (720 ELISA units inactivated HAV)	IM	0, 6–12 months	None
		≥19	1 mL (1,440 ELISA units inactivated HAV)	IM	0, 6–12 months	None
HepA, inactivated (2 doses)	Vaqta (Merck)	1–18	0.5 mL (25 units HAV antigen)	IM	0, 6–18 months	None
		≥19	1 mL (50 units HAV antigen)	IM	0, 6–18 months	None
Combined HepA and HepB* (3 doses)	Twinrix (GlaxoSmithKline)	≥18 (primary)	1 mL (720 ELISA units inactivated HAV + 20 µg HBsAg)	IM	0, 1, 6 months	None
		≥18 (accelerated)	1 mL (720 ELISA units inactivated HAV + 20 µg HBsAg)	IM	0, 7, 21–30 days	12 months

Abbreviations: ELISA = enzyme-linked immunosorbent assay; HAV = hepatitis A virus; HBsAg = hepatitis B surface antigen; HepA = hepatitis A; HepB = hepatitis B; IM = intramuscular.

* Combined HepA and HepB vaccine (Twinrix) should not be used for postexposure prophylaxis.

TABLE 2. Dosage recommendations for GamaSTAN human immune globulin for preexposure and postexposure prophylaxis against hepatitis A infection

Indication	Time	Dose*	Route
Preexposure prophylaxis	Up to 1 month duration of travel	0.1 mL/kg	IM
Preexposure prophylaxis	Up to 2 months duration of travel	0.2 mL/kg	IM
Preexposure prophylaxis	≥2 months duration of travel	0.2 mL/kg (repeat every 2 months)	IM
Postexposure prophylaxis	Within 2 weeks of exposure	0.1 mL/kg	IM

Abbreviation: IM = intramuscular.

* The dosage of immune globulin is based on weight for all ages and does not have a maximum dose for protection against hepatitis A (Source: Grifols. Treating with GamaSTAN [immune globulin (human)] Los Angeles, CA: Grifols, 2019. <https://www.hypermunes.com/en/hcp/gamastan-hepatitis-a>).

recommended, they should be administered at least 2 weeks before (205,218) or at least 6 months after the administration of hepatitis A IG (217); the GamaSTAN package insert includes additional information (217). If an IG preparation must be administered <2 weeks after the administration of MMR or varicella vaccine, the patient should be revaccinated no sooner than 6 months after receipt of the IG preparation (205,217).

Vaccine-Induced Seroprotection

Immunogenicity in Infants

Available data indicate that inactivated HepA vaccines are immunogenic in children aged <2 years who do not have passively acquired maternal antibodies (see Factors Associated with Reduced Immunogenicity). All such children administered HepA vaccine subsequently had protective antibody levels, with the final geometric mean concentration (GMCs) varying depending on the dose and schedule (220–226). Infants (aged <12 months) with passively acquired maternal antibodies had reduced GMCs after vaccination (221,222).

Immunogenicity in Children and Adolescents

HepA vaccines are highly immunogenic when administered to children and adolescents, according to studies using different formulations and vaccine schedules. A total of 97%–100% of persons aged 2–18 years had protective levels of antibody 1 month after receiving the first dose, and 100% had protective levels 1 month after the second dose, with high GMCs (215,225,227–233).

Immunogenicity in Adults

All licensed HepA vaccines are highly immunogenic in adults aged >18 years when administered according to the recommended schedules (215,229,230,234,235). Limited data are available regarding the timing needed to develop protective antibodies. A retrospective pooled analysis of four 2-dose vaccination studies compared the immunogenicity and safety of the inactivated HepA vaccine in adults aged ≥40 years with adults aged 20–30 years. The immune response was similar among the age groups at 1 month after the first dose (91%–99.7%) and second dose (95.3%–100%). However, the seroconversion rate was higher at 15 days among adults aged 20–30 years (92.3%; 95% CI: 84–97) than among adults ≥40 years (79.7%; 95% CI: 68.8–88.2) (234). For Twinrix, the percentage of persons with seroconversion for hepatitis A was 93.8% after 1 dose, 98.8% after 2 doses, and 99.9% 1 month after 3 doses, using the standard Twinrix schedule; the Twinrix package insert provides additional information (202).

Efficacy

The efficacy of Havrix was evaluated in a double-blind, randomized controlled clinical trial conducted in Thailand among approximately 40,000 children aged 1–16 years. The children were living in villages with rates of HAV infection of 119 cases per 100,000 population, determined by active surveillance during 1989–1991 (236). After 2 doses of vaccine (360 ELISA units per dose) administered 1 month apart, the efficacy of vaccine in protecting against clinical hepatitis A was 94% (95% CI: 79%–99%). A double-blind, placebo-controlled, randomized clinical trial using Vaqta was conducted among approximately 1,000 children aged 2–16 years living in a New York community where 68% percent of persons aged >19 years had detectable levels of antibody (237). The protective efficacy against clinical hepatitis A was 100% (lower bound of the 95% CI: 87%) after administration of 1 dose (25 units) of vaccine. The efficacy of Twinrix is expected to be similar to the efficacy for each of the monovalent HepA and HepB vaccine components; the Twinrix package insert provides additional information (202).

Long-Term Protection

Lifelong protection occurs after natural HAV infection and might occur after vaccination, although the exact duration of protection against HAV infection after vaccination is unknown. Long-term immunogenicity studies have been performed among children vaccinated as children, adults vaccinated as children, and adults vaccinated as adults.

Children vaccinated at age <24 months. Anti-HAV seropositivity persisted until at least ages 15–16 years among three groups of Alaska Native children for whom a 2-dose inactivated HepA vaccination series was initiated at ages 6–21 months (238). However, among vaccinated infants and children whose mothers were anti-HAV–positive, the prevalence of seropositivity decreased after age 10 years, possibly because of the effect of passively acquired maternal antibodies on immune response. Modeling suggested that seropositivity should persist for most persons for at least 30 years (238).

Adults vaccinated as children. Anti-HAV has been shown to persist above protective levels for at least 22 years in the majority of adults administered inactivated vaccine on a 3-dose schedule as children (aged 3–6 years) (239,240), although the overall GMC decreased to 90 mIU/mL, and 12% of participants had anti-HAV levels of <20 mIU/mL, indicating waning anti-HAV (240). Vaccine recipients vaccinated as children with the previously recommended 3-dose HepA Havrix (360 ELISA units per dose) schedule were found to have similar protection approximately 14 years after vaccination to those vaccinated with the 2-dose schedule (720 ELISA units) (241).

Adults vaccinated as adults. Antibody persistence was measured annually in two randomized double-blind studies of adults who received Havrix 1440 ELISA units with a 2-dose schedule of 0–6 months or 0–12 months in 1992–1993 (242,243). Twenty years after vaccination >97% of adults were seropositive for anti-HAV antibodies. GMCs were 312 mIU/ml in 34 of 36 participants vaccinated initially with a 2-dose schedule at 0–6 months and 317 mIU/ml in 85 of 86 subjects vaccinated at 0–12 months. During 20 years of follow-up, six of seven participants who lost circulating anti-HAV antibodies mounted a strong response after HepA vaccine booster administration. Mathematical modeling predicted that seropositive anti-HAV levels would persist in ≥95% of vaccinees at year 30 and ≥90% at year 40 (243).

Periodic assessments of duration of protection continue to be conducted. Although evidence of waning anti-HAV exists, anamnestic response to HepA booster doses indicates persistent immune memory and protection against HAV infection (144,243). Cellular immunity also might contribute to long-term protection.

Single-Dose Hepatitis A Vaccine Protection

Protective anti-HAV antibody levels after a single dose of inactivated HepA vaccine can persist for almost 11 years and increase or reappear after booster vaccination among studies assessing long-term protection up to 10.67 years after a 1-dose vaccination (244). In addition, a single dose of HepA vaccine has been shown to induce HAV-specific cellular immunity similar to that induced by natural infection (245). A single-dose of single-antigen HepA vaccine has also been shown to control outbreaks of hepatitis A (246).

Universal single-dose childhood vaccination programs have been initiated in some South American countries. In 2014, single-dose universal vaccination was adopted by the National Immunization Program of Brazil for children aged 15–24 months (247). A significant decrease in HAV cases occurred among children aged <5 years during 2014–2017, from 949 cases to 31 cases ($p = 0.017$) (248). Single-dose HepA vaccination was implemented for all Argentinean children at age 12 months in 2005. Protective antibody levels against HAV were found in more than 97% (1,060 of 1,088) of Argentinean children up to age 9 years after single-dose HepA vaccination (249) and in approximately 87.6% of 1,119 children tested up to 11 years after single-dose vaccination (250). Additional data are needed to assess long-term protection after a single dose.

Factors Associated with Reduced Immunogenicity

Presence of Passively Acquired Maternal Antibodies

The presence of passively acquired maternal anti-HAV at the time of infant (aged <12 months) vaccination interferes with the immune response to HepA vaccination and substantially reduces the anti-HAV concentration after vaccination (220,221,224,251). In the majority of studies, although all infants subsequently had protective levels of antibody, the final GMCs were approximately one third to one tenth the GMCs of infants born to anti-HAV–negative mothers and vaccinated according to a single, consistent schedule (252). Despite lower antibody levels after the primary series, the majority of infants with passively acquired antibody had an anamnestic response to a booster dose administered 1–6 years later (221,252,253). Passively acquired antibody decreased to undetectable levels in the majority of infants by age 1 year (220,254). HepA vaccine is highly immunogenic for children who begin vaccination at age >1 year, regardless of maternal anti-HAV status (220,221).

Concurrent Administration of Hepatitis A Vaccine and Immune Globulin

Although GMCs of adults who received IG and vaccine were lower 1 month after completion of the vaccine series than the GMCs of adults who had been administered HepA vaccine alone, the proportion of adults who subsequently had protective levels of antibody did not differ (255,256). Therefore, the effect of reduced GMCs on long-term protection is unknown.

Immunocompromising Conditions

The humoral response to HepA vaccine might be reduced in immunocompromised children and adults (e.g., hematopoietic cell transplant [HCT] recipients, patients undergoing chemotherapy, and persons with HIV infection) (Table 3) (4,257–259). Limited data suggest that modified dosing regimens, including a doubling of the standard antigen dose or administration of additional doses, might increase response rates. In addition, ACIP best practice guidance states that HCT recipients who received vaccines before their HCT should be vaccinated or revaccinated routinely after HCT, regardless of the source of the transplanted stem cells; revaccination doses of HepA vaccine are recommended after HCT (205).

The Infectious Disease Society of America has guidance for vaccination of the immunocompromised host. The guidance states that solid organ transplant candidates who are unvaccinated, undervaccinated, or seronegative for hepatitis A, particularly liver transplant candidates, aged 12–23 months (strong recommendation, moderate-quality evidence) and ≥2 years (strong recommendation, moderate-quality evidence) should receive a HepA vaccine series (4).

TABLE 3. Categories of persons with increased risk for hepatitis A virus infection or severe disease from hepatitis A virus infection*

Type of risk	Risk category	Examples
Increased risk for HAV infection	Close personal contacts of persons with HAV infection [†]	Household contacts Caretakers Sexual contacts Persons who anticipate close personal contact with an international adoptee
	Occupational risk	Persons working with nonhuman primates Persons working with clinical or nonclinical material containing HAV in a research laboratory
	Persons who use drugs Persons in settings where services to adults are provided	Persons who use injection or noninjection drugs (i.e., all those who use illegal drugs) Group settings for persons with developmental disabilities Homeless shelters Syringe services programs Correctional facilities during outbreaks
	International travelers	Persons traveling to or working in countries with high or intermediate HAV endemicity
Increased risk for severe disease from HAV infection	Immunocompromised persons	Congenital or acquired immunodeficiency HIV infection Chronic renal failure, undergoing dialysis Solid organ, bone marrow, or stem cell transplant recipients Persons with diseases requiring treatment with immunosuppressive drugs/biologics (e.g., tumor necrosis alpha inhibitors), long-term systemic corticosteroids, radiation therapy
	Persons with chronic liver disease	Hepatitis B virus infection Hepatitis C virus infection Cirrhosis (any etiology) Fatty liver disease (hepatic steatosis) Alcoholic liver disease Autoimmune hepatitis Alanine aminotransferase or aspartate amino transferase level more than twice the upper limit of normal or persistently elevated for 6 months
	Age	Adults aged >40 years

Abbreviations: HAV = hepatitis A virus; HIV = human immunodeficiency virus.

* Not all risk categories include persons recommended for routine hepatitis A vaccination (Box). Providers should assess the risk for HAV infection or severe disease from HAV infection when making decisions regarding the provision of postexposure prophylaxis or revaccination (Table 4). Providers should consider vaccination in settings providing services to adults at risk for HAV infection (see Implementation Strategies and Hepatitis A Vaccination During Outbreaks).

[†] Excludes health care personnel using appropriate personal protective equipment.

Lower CD4 Counts and Other Factors Among Persons with HIV Infection

HepA vaccine using a standard dose and schedule is immunogenic for children and adults with HIV infection (143,144,260,261). Although those with higher CD4 counts (>200–300 cells/mm³) respond nearly as well as persons who are not immunocompromised, adults with lower CD4 counts are less likely to acquire protective levels of antibody (139,141,145–147,257,260,262). This finding suggests that immunologic reconstitution with antivirals might restore the ability to respond to vaccination (263). Most adults with well-controlled HIV infections had durable seropositive responses up to 6–10 years after HepA vaccination (145). In one study, protective antibodies developed in 100% of 32 children with HIV infection (mean age: 5.5 years) (264). Factors associated with seroreversion (loss of seroresponse) in persons with HIV infection who had an initial seroconversion include higher weight (overweight and obese), lower CD4 count or HIV viremia at the time of HepA vaccination, or lower or delayed seroresponse to vaccination (146).

Chronic Liver Disease

Vaccination of children or adults with chronic liver disease of viral or nonviral etiology produced seroprotection proportions similar to those observed in healthy adults (Table 3) (265–270). Seroprotection in liver transplant recipients is highly variable. In one study, none of the eight patients who were vaccinated after liver transplantation responded to HepA vaccination; in another study, six (26%) of 23 liver transplant recipients responded (265,266). However, HepA vaccine was immunogenic for most liver transplant patients in another study, with 38 (97%) responding to a standard dose and schedule (271,272) (see Immunocompromising Conditions).

Older Age (Aged >40 Years)

Limited data suggest that persons vaccinated at an older age might have a lower immune response to HepA vaccine than younger persons. In certain studies, persons vaccinated at age >40 years had lower rates of seroprotection than persons vaccinated at age ≤40 years, particularly when levels were measured within 15 days of the first dose, but had similar

seroprotection rates after two doses, despite lower final antibody levels (229,234,235,273–275).

Other Factors

A slower antibody response to HepA vaccine has been observed in overweight persons (146,273), and one study among persons with HIV infection found that seroreversion was more likely when persons were overweight or obese (146). Smoking, a factor associated with decreased immunogenicity to other vaccines, has not been evaluated for the licensed formulations of HepA vaccine.

Vaccine Safety

Administration of Hepatitis A Single-Antigen and Combination Vaccines

In prelicensure clinical trials, the most common adverse events following vaccination with Havrix and Vaqta (HepA) and Twinrix (combination HepA and HepB) were injection site reactions (e.g., pain and erythema) and mild systemic reactions (e.g., fever, irritability, loss of appetite, drowsiness, and headache). Rates of adverse events following Twinrix vaccination were similar to those observed with separately administered HepA and HepB vaccines.

VAERS, a spontaneous reporting (passive surveillance) system managed by CDC and FDA, is used to conduct post-licensure safety monitoring of U.S. vaccines (18). During 2006–2018, VAERS received 25,079 U.S. reports involving HepA vaccines, of which 5.7% were classified as serious (i.e., one or more of the following was reported: death, life-threatening illness, hospitalization or prolongation of existing hospitalization, or permanent disability) (276). Among all reports, 48.6% were in persons aged 2–18 years, 29.5% in children aged 12–23 months, and 13.3% in adults aged >19 years. Most (80.3%) reports involved HepA vaccines administered concomitantly with other vaccines during the same health care visit. The most frequently reported adverse events were fever (16.2%), injection site erythema (14.8%), injection site swelling (9.9%), rash (9.0%), and erythema (8.9%) (CDC, unpublished data, 2006–2018).

During the same period (2006–2018), VAERS received 2,117 U.S. reports involving the combination HepA and HepB vaccine, of which 8.6% were classified as serious. Among all reports, 92.9% were in persons aged ≥18 years (the approved age for the licensed vaccine). A majority (60.3%) of reports involved combination Twinrix vaccine administered concomitantly with other vaccines during the same health care visit. The most frequently reported adverse events were fever (13.6%), headache (11.5%), pain (11.5%), injection site pain (9.8%), and dizziness (9.4%) (CDC, unpublished data, 2006–2018).

VAERS is subject to the limitations of spontaneous reporting systems in general and is not designed to assess whether a vaccine caused an adverse event. However, these findings in VAERS for HepA vaccine and combination Twinrix vaccine are similar to findings for other inactivated vaccines routinely administered in these age groups.

The data on HepA vaccination during pregnancy are limited. A published safety review of 139 reports to VAERS during 1996–2013 of women who received HepA vaccine or combination Twinrix vaccine while pregnant did not identify any concerning patterns of adverse events in the pregnant women or their infants (277).

A multisite study (278) in CDC's Vaccine Safety Datalink (VSD), a population-based research and surveillance data system (20), of maternal HepA vaccination found that HepA vaccine administration during pregnancy was not associated with increased risk for a range of adverse events examined among pregnancies resulting in live births. However, an association was found between maternal HepA vaccination and infants who were small for gestational age. Investigators believe this association was likely due to unmeasured confounding but might warrant additional consideration (278).

Persons who have had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of HepA vaccine or have severe allergy to a HepA vaccine component should not receive HepA vaccine (205). Persons who have a moderate or severe acute illness with or without fever might want to defer vaccination while the acute illness is present (205).

Simultaneous Administration with Other Vaccines

Available data do not indicate a reduced response when HepA vaccine is administered with other vaccines among children and adults (221,279–285); additional information is available from the manufacturer package inserts (202). Limited data from studies conducted among adults indicate that simultaneous administration of HepA vaccine with diphtheria, poliovirus (oral and inactivated), tetanus, typhoid (both oral and intramuscular), cholera, Japanese encephalitis, rabies, or yellow fever vaccines does not decrease the immune response to either vaccine or increase the frequency of adverse events (279–281). Studies conducted before the licensure of Twinrix in the United States indicated that HepB vaccine can be administered simultaneously with HepA vaccine without either decreasing vaccine immunogenicity or increasing the frequency of adverse events (282,283).

Studies conducted among infants and young children aged <18 months have demonstrated that simultaneous administration of HepA vaccine with diphtheria-tetanus-acellular pertussis (DTaP), *Haemophilus influenzae* type b (Hib), HepB, MMR, or inactivated poliovirus vaccines does

not affect the immunogenicity and reactogenicity of these vaccines (202,221,283,284). Administration of 1 or 2 doses of Vaqta was well tolerated and highly immunogenic in approximately 4,300 children aged 12–23 months, whether given alone or concomitantly with other vaccines (M-M-RII, Varivax, Tripedia, Prevnar, ProQuad, PedvaxHIB, and Infanrix) in the United States (285).

Cost-Effectiveness Considerations

The cost-effectiveness of nationwide routine HepA vaccination was evaluated in an analysis published in 2007 that used a Markov model to follow a single U.S. birth cohort of approximately 4 million persons from birth in 2005 through age 95 years or death (286). Compared with no vaccination, routine vaccination at age 1 year would prevent 172,000 infections at a cost of \$28,000 per quality-adjusted life year (QALY) saved. Compared with maintaining the levels of HepA vaccination under the preexisting regional policy in the 1996 and 1999 ACIP recommendations (6,7), universal routine vaccination at age 1 year would prevent an additional 112,000 infections, at a cost of \$45,000 per QALY saved (286). Another economic analysis that considered the estimated reduction in secondary cases among household contacts of infected children yielded similar results (287).

After implementation of the 2006 universal HepA childhood vaccination recommendations (8), in 2015 the original Markov model was adapted to assess the cost-effectiveness of catch-up HepA vaccination among unvaccinated and partially vaccinated children compared with unvaccinated children, using hepatitis A incidence rates during 2008–2012 (288). Over the lifetime of the cohort, catch-up HepA vaccination would reduce the total number of infections relative to the baseline by 741 while increasing doses of vaccine administered by 556,989. Catch-up vaccination would increase net cost by \$10.2 million, or \$2.38 per person (288). The model's conclusions were highly sensitive to the discount rate (3%), rate of adult vaccination, and the incidence of HAV infection. Although vaccination rates among adults have persisted at low levels (289), the hepatitis A incidence rate and child and adolescent vaccination rates are substantially higher than when this model was developed (9,14). Therefore, the actual cost-effectiveness of catch-up vaccination is likely more favorable now than originally estimated.

Recommendations for Hepatitis A Vaccine and Immune Globulin for Preexposure Prophylaxis

This section contains ACIP recommendations for routine HepA vaccination among children, adolescents, and adults (Box) and guidance for the prevention of HAV infection

BOX. Prevention of hepatitis A virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020*

Children

- All children aged 12–23 months
- Unvaccinated children and adolescents aged 2–18 years

Persons at increased risk for HAV infection

- International travelers
- Men who have sex with men
- Persons who use injection or noninjection drugs (i.e., all those who use illegal drugs)
- Persons with occupational risk for exposure
- Persons who anticipate close personal contact with an international adoptee
- Persons experiencing homelessness

Persons at increased risk for severe disease from HAV infection

- Persons with chronic liver disease
- Persons with human immunodeficiency virus infection

Other persons recommended for vaccination

- Pregnant women at risk for HAV infection or severe outcome from HAV infection
- Any person who requests vaccination

Vaccination during outbreaks

- Unvaccinated persons in outbreak settings who are at risk for HAV infection or at risk for severe disease from HAV

Implementation strategies for settings providing services to adults

- Persons in settings that provide services to adults in which a high proportion of those persons have risk factors for HAV infection

Hepatitis A vaccination is no longer recommended by ACIP

- Persons who receive blood products for clotting disorders (e.g., hemophilia)

* See the Recommendations for Hepatitis A Vaccine and Immune Globulin for Preexposure Prophylaxis section in this report for additional information.

using IG for preexposure and postexposure prophylaxis. HepA vaccination is also recommended by ACIP for postexposure prophylaxis and for persons at risk during outbreaks. IG provides short-term protection against HAV infection and is recommended in certain situations (Tables 2 and 4).

The following recommendations for HepA vaccination are intended to further reduce hepatitis A morbidity and mortality in the United States and make possible consideration of eventual elimination of HAV transmission. HepA vaccination is recommended routinely for children, persons at increased risk for infection, persons at increased risk for severe disease from HAV infection, and any person who requests vaccination.

Children

- ACIP recommends Hep A vaccination for all children aged 12–23 months,
- ACIP recommends that all children and adolescents aged 2–18 years who have not previously received HepA vaccine be vaccinated (i.e., children and adolescents are recommended for catch-up vaccination). This is a new recommendation.

Persons at Increased Risk for HAV Infection

Persons Traveling to or Working in Countries with High or Intermediate HAV Endemicity

All susceptible persons (i.e., unvaccinated, partially vaccinated, or never infected) traveling to or working in countries that have high or intermediate hepatitis A endemicity (Figure 3) are at increased risk for HAV infection. These persons should be vaccinated, or receive IG if too young or contraindicated for vaccine, before departure (17,218). For travelers who are partially vaccinated already (i.e., did not receive a full vaccine series), a dose should be administered before travel if needed according to the vaccine schedule.

Infants

Infants aged <6 months. Infants aged <6 months should receive IG before travel when protection against HAV is recommended. For travel duration up to 1 month, 1 dose of IG at 0.1 mL/kg is recommended; for travel up to 2 months, 1 dose of IG at 0.2 mL/kg is recommended, and for travel of ≥2 months, a 0.2 mL/kg dose of IG should be repeated every 2 months for the duration of travel or until the infant is administered HepA vaccine (i.e., at age ≥6 months) (Tables 2 and 4).

Infants aged 6–11 months. HepA vaccine should be administered to infants aged 6–11 months traveling outside the United States when protection against HAV is recommended (Table 4). The travel-related dose for infants aged 6–11 months

does not count toward the routine 2-dose series. Therefore, the 2-dose HepA vaccination series should be initiated at age 1 year with the appropriate dose and schedule.

CDC clinical guidance. IG (GamaSTAN) cannot be administered simultaneously with MMR vaccine because antibody-containing products such as IG can inhibit the immune response to measles and rubella vaccines for up to 6 months after administration (217). However, because MMR vaccine is recommended for all infants aged 6–11 months traveling internationally from the United States (290), and because measles in infancy is more severe than HAV infection in infancy, measles prevention should be prioritized, and IG should not be administered. HepA vaccine (indication for off-label use) and MMR vaccine can be administered simultaneously to infants aged 6–11 months (220,221,251), providing protection against both hepatitis A and measles (17,205,284).

Persons Aged ≥12 Months

Healthy persons aged 12 months through 40 years. Healthy persons aged 12 months through 40 years who are planning on traveling to an area with high or intermediate hepatitis A endemicity and who have not received HepA vaccine should receive a single dose of HepA vaccine as soon as travel is considered and should complete the HepA vaccine series with the appropriate dose and schedule (Table 4).

Persons aged >40 years, persons with immunocompromising conditions, and persons with chronic liver disease. Persons aged >40 years, persons with immunocompromising conditions, and persons with chronic liver disease planning on traveling to an area with high or intermediate HAV endemicity should receive a single dose of HepA vaccine as soon as travel is considered. Persons traveling in <2 weeks should receive the initial dose of HepA vaccine and simultaneously may be administered IG in a different anatomic injection site (e.g., separate limbs) (218,268,269,291). The HepA vaccine series should be completed according to the routine schedule (Table 4).

CDC clinical guidance. In addition to HepA vaccine, IG should be considered before travel for persons with special risk factors or increased risk for severe disease from HAV infection (Table 3) (Appendix A).

Travelers for whom vaccine is contraindicated and persons who choose not to receive HepA vaccine. Travelers for whom vaccine is contraindicated or who choose not to receive vaccine should receive IG before travel when protection against HAV is recommended. For travel duration up to 1 month, 1 dose of IG at 0.1 mL/kg is recommended; for travel up to 2 months, 1 dose of IG at 0.2 mL/kg is recommended, and for travel of ≥2 months, a 0.2 mL/kg dose of IG should be repeated every 2 months for the duration of travel (Tables 2 and 4).

Men Who Have Sex with Men

Vaccination is recommended for MSM. Health care providers in primary care and specialty medical settings in which MSM receive care (e.g., sexually transmitted disease clinics) should offer HepA vaccine to all MSM.

Persons Who Use Injection or Noninjection Drugs

Vaccination is recommended for persons who use injection or noninjection drugs (i.e., all those who use illegal drugs). Health care providers should conduct a thorough risk factor assessment to identify persons who use or are at risk for using injection or noninjection drugs. Health care providers in primary care and specialty medical settings in which persons who use drugs receive care (e.g., opioid treatment programs that provide medication-assisted treatment to persons with an opioid use disorder) should offer HepA vaccine to all persons who use injection or noninjection drugs.

Persons with Occupational Risk for Exposure

Persons who work with HAV-infected nonhuman primates or with clinical or nonclinical material containing HAV in a research laboratory setting should be vaccinated. No other occupational groups (e.g., health care providers or food handlers) have been demonstrated to be at increased risk for HAV infection because of occupational exposure.

Persons Who Anticipate Close Personal Contact with an International Adoptee from a Country with High or Intermediate Endemicity

All persons who anticipate close personal contact (e.g., household contact, caretaker, or regular babysitter) with an international adoptee from a country with high or intermediate endemicity during the first 60 days following arrival of the adoptee in the United States should be vaccinated against hepatitis A (16). The first dose of the HepA vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

Persons Experiencing Homelessness

All persons aged ≥1 year experiencing homelessness should be routinely vaccinated against hepatitis A. HepA vaccine should be integrated into routine preventive services for persons experiencing homelessness (15).

Persons at Increased Risk for Severe Disease from HAV Infection

Persons with Chronic Liver Disease

Persons with chronic liver disease (including but not limited to persons with HBV infection, HCV infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis,

TABLE 4. Recommendations for postexposure prophylaxis and preexposure protection, by age group and risk category — Advisory Committee on Immunization Practices, 2020

Indication and age group	Risk category and health status	HepA vaccine	IG*
Postexposure prophylaxis			
<12 months	Healthy	No	0.1 mL/kg
12 months–40 yrs	Healthy	1 dose†	None
>40 yrs	Healthy	1 dose†	0.1 mL/kg [§]
≥12 months	Immunocompromised or chronic liver disease	1 dose†	0.1 mL/kg [¶]
≥12 months	Vaccine contraindicated**	No	0.1 mL/kg
Preexposure protection (e.g., travel)††			
<6 months	Healthy	No	0.1–0.2 mL/kg ^{§§}
6–11 months	Healthy	1 dose ^{¶¶}	None
12 months–40 yrs	Healthy	1 dose***	None
>40 yrs	Healthy	1 dose***	0.1–0.2 mL/kg ^{§§,†††}
>6 months	Immunocompromised or chronic liver disease	1 dose***	0.1–0.2 mL/kg ^{§§,†††}
>6 months	Persons who elect not to receive vaccine or for whom vaccine is contraindicated**	No	0.1–0.2 mL/kg ^{§§}

Abbreviations: HAV = hepatitis A virus; HepA = hepatitis A; IG = immune globulin.

- * Measles, mumps, and rubella vaccine should not be administered for at least 2 weeks before and 6 months after administration of IG.
- † A second dose of HepA vaccine is not required for postexposure prophylaxis; however, for long-term immunity, the vaccination series should be completed with a second dose at least 6 months after the first dose.
- § The provider’s risk assessment (Table 3) should determine the need for IG administration. If the provider’s risk assessment determines that both vaccine and IG are warranted, HepA vaccine and IG should be administered simultaneously in a different anatomic site (e.g., separate limbs).
- ¶ Vaccine and IG should be administered simultaneously in a different anatomic site (e.g., separate limbs).
- ** Life-threatening allergic reaction to a previous dose of HepA vaccine or allergy to any vaccine component.
- †† IG should be considered before travel for persons with special risk factors for either HAV infection or severe disease from HAV infection.
- §§ 0.1 mL/kg for travel up to 1 month; 0.2 mL/kg for travel up to 2 months, 0.2mL/kg every 2 months for travel of ≥2 months’ duration.
- ¶¶ This dose should not be counted toward the routine 2-dose series, which should be initiated at age 12 months.
- *** For persons not previously vaccinated with HepA vaccine, administer dose as soon as travel is considered, and complete series according to routine schedule if the next dose is needed before travel.
- ††† May be administered based on provider’s risk assessment (Table 3).

or an ALT or AST level persistently greater than twice the upper limit of normal) should be routinely vaccinated against hepatitis A.

Persons with HIV Infection

Persons aged ≥ 1 year. ACIP recommends all persons with HIV infection aged ≥ 1 year be routinely vaccinated with HepA vaccine. This is a new recommendation.

CDC clinical guidance. Because the response to the vaccine might be reduced in persons with HIV infection who are immunosuppressed, postvaccination serologic testing should be performed for all persons with HIV infection ≥ 1 month after completing the HepA vaccine series (292). Some studies have shown that ≥ 6 months is needed for persons with HIV infection to seroconvert (i.e., ≥ 10 mIU/mL) after vaccination (146,257,293,294).

Although persons with HIV infection who have lower CD4 cell counts or percentages might have a weaker response to the vaccine, vaccination should not be delayed until the CD4 count exceeds a certain threshold because of the prolonged risk for HAV exposure created by missed opportunities to vaccinate. Persons with HIV infection who do not respond to the vaccine should be considered susceptible to HAV infection and counseled about precautions to prevent infection, as well as the need to obtain IG postexposure prophylaxis (PEP) for any known or likely exposure to HAV. Health care providers should consider revaccination (repeat vaccine series) for persons with HIV infection who did not demonstrate an adequate immune response (i.e., ≥ 10 mIU/mL) after the initial HepA vaccination series, particularly persons with HIV infection who later demonstrate improvement in immune status (e.g., increased CD4 counts and decreased HIV viral load) (292). At least 1 month after revaccination with a complete vaccine series, postvaccination testing should be performed. If the response to revaccination is still not adequate (i.e., < 10 mIU/mL), additional vaccination is not recommended; however, the person should be counseled concerning methods to prevent HAV infection, including the need for IG after an exposure (see Revaccination).

All persons with HIV infection who received HepA vaccine, regardless of postvaccination serologic testing results, should be counseled that the vaccine might not provide long-term protection against HAV infection. Therefore, they might need to receive IG after a high-risk HAV exposure (e.g., a sexual or household contact) (146,295).

Other Persons Recommended for Vaccination

Pregnant Women

Pregnant women at risk for HAV infection or severe outcome from HAV infection. ACIP recommends that pregnant women who are identified to be at risk for HAV infection during pregnancy (e.g., international travelers, persons who use injection or noninjection drugs, persons who have occupational risk for infection, persons who anticipate close personal contact with an international adoptee, or persons experiencing homelessness) or for having a severe outcome from HAV infection (e.g., persons with chronic liver disease or persons with HIV infection) should be vaccinated during pregnancy if not previously vaccinated. This is a new recommendation.

CDC clinical guidance. Pregnant women should be vaccinated for the same indications as nonpregnant women. Unvaccinated or partially vaccinated pregnant adolescents should receive HepA catch-up vaccination. Pregnant women at risk for HAV infection during pregnancy should be counseled concerning other prevention methods (e.g., hand hygiene) to prevent HAV infection.

Any Person Who Requests Vaccination

Disclosure of a risk factor for HAV infection or complication is not necessary for HepA vaccination. Because a person might not disclose a risk factor to the provider, ACIP recommends that any person who has not previously completed the HepA vaccine series may receive HepA vaccine.

Implementation Strategies for Settings Providing Services to Adults

Settings in which a high proportion of persons have risk factors for HAV infection include health care settings that focus on persons who use injection or noninjection drugs, as well as group homes and nonresidential day care facilities for persons with developmental disabilities. Health care providers may assume that unvaccinated adults aged ≥ 19 years in these settings are at risk for HAV infection and offer HepA vaccination to those who have not previously completed vaccination.

- HepA vaccination may be offered in outreach and other settings in which services are provided to persons at risk for HAV infection (e.g., homeless shelters and syringe services programs).
- Health care providers should consider implementing standing orders to identify adults recommended for HepA vaccination and administer vaccination as part of routine services.

- HepA vaccination should be considered for persons (e.g., residents and staff) in facilities where hygiene is difficult to maintain (e.g., group homes for persons with development disabilities, and homeless shelters.)

ACIP Recommendations for Hepatitis A Vaccine and Immune Globulin for Postexposure Prophylaxis

Guidance for providers on risk assessment and clinical decision-making for HAV PEP is provided (Appendix B). In the absence of PEP, secondary attack rates of 20%–50% have been reported in households with higher rates of transmission occurring from infected young children than from infected adolescents and adults (34,35,296,297). Persons who have been exposed to HAV within the last 2 weeks (e.g., a sexual or household contact or known contaminated food source) and who have not been vaccinated previously should be administered 1 dose of single-antigen HepA vaccine, IG (0.1 mL/kg), or both (persons aged ≥ 12 months who are immunocompromised or have chronic liver disease) as soon as possible (17,218). Using HepA vaccine for PEP has advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability (17). The efficacy of IG or vaccine administered >2 weeks after exposure has not been established.

Attack rates among persons exposed to HAV-infected food handlers are low (171,173); most food handlers with HAV infection do not transmit HAV through the workplace to exposed consumers or restaurant patrons (36,170,171).

Severely immunocompromised persons, including those who receive routine IG administration for immunocompromising conditions, who have been vaccinated in the past may benefit from PEP and should be assessed on an individual basis for risk for HAV infection.

HepA vaccine should be administered as soon as possible, within 2 weeks of exposure, to all unvaccinated persons aged ≥ 12 months who have recently been exposed to HAV (17). In addition to HepA vaccine, coadministration of GamaSTAN IG (0.1 mL/kg) is recommended under certain circumstances (Table 4) and for persons aged >40 years based on the provider's risk assessment (17).

Infants Aged <12 Months

Infants aged <12 months should receive IG (0.1 mL/kg) (17,218) instead of HepA vaccine as soon as possible within 2 weeks of exposure. MMR vaccine should not be administered <6 months after IG administration (217); the GamaSTAN package insert includes additional information (217).

Persons Aged ≥ 12 Months

Healthy Persons Aged ≥ 12 Months

Persons aged ≥ 12 months who have been exposed to HAV within the past 2 weeks and have not previously completed the HepA vaccine series should receive 1 dose of single-antigen HepA vaccine (Table 4) as soon as possible. In addition to HepA vaccine, IG (0.1 mL/kg) may be administered to persons aged >40 years depending on the provider's risk assessment (Appendix B). When the dose of HepA vaccine administered for PEP is the first dose the exposed person has received, a second dose should be administered 6 months after the first for long-term immunity; however, the second dose is not necessary for PEP.

Persons Aged ≥ 12 Months Who Are Immunocompromised or Have Chronic Liver Disease

Persons who are immunocompromised or have chronic liver disease and who have been exposed to HAV within the past 2 weeks and have not previously completed the HepA vaccination series should receive both IG (0.1 mL/kg) and HepA vaccine simultaneously in a different anatomic site (e.g., separate limbs) as soon as possible after exposure (17,268,269,291) (Table 4). When the dose of HepA vaccine administered for PEP is the first dose the exposed person has received, a second dose should be administered 6 months after the first for long-term immunity; however, the second dose is not necessary for PEP.

Persons for Whom Vaccine is Contraindicated

Persons for whom vaccine is contraindicated (see Vaccine Safety) should receive IG (0.1 mL/kg) (17,218) instead of HepA vaccine as soon as possible within 2 weeks of exposure. MMR and varicella vaccines should not be administered <6 months after IG administration (217); the GamaSTAN package insert includes additional information (217).

CDC Clinical Guidance for Postexposure Prophylaxis

In addition to HepA vaccine, IG should be considered for PEP for persons with special risk factors for either HAV infection or severe disease from HAV infection (Tables 3 and 4) (Appendix B). The combination HepA and HepB vaccine, Twinrix, contains 720 ELISA units of hepatitis A antigen, which is half of the single-antigen HepA vaccine adult dose. Because no data are available for use of Twinrix for PEP, Twinrix is not recommended for use as PEP.

Vaccination During Outbreaks

Preexposure Vaccination of Populations at Risk

Vaccination strategies for outbreak control should focus on preexposure vaccination of populations at risk for infection and postexposure strategies. The best way to prevent HAV infection is through vaccination of at-risk populations. There is limited available evidence indicating the level of vaccine coverage needed to control a hepatitis A outbreak (84,246,298). For routine vaccination, the number and timing of doses depends on the type of vaccine administered; however, a single dose of HepA vaccine is adequate for outbreak control (246). Providers should complete the HepA vaccine series when feasible; however, completion of the series, although recommended for long-term protection, is not required for PEP or an outbreak response.

Certain populations at risk for HAV infection (e.g., persons who use injection or noninjection drugs or persons experiencing homelessness) in an outbreak might be difficult to reach with routine vaccination and education efforts because of various factors (e.g., behavioral health issues, limited or no engagement in the health care system and other institutions, and lack of transportation). Often, health departments and health care providers must supplement traditional outreach strategies with other approaches (e.g., mobile field vaccination, stationary points of dispensary, and vaccination foot teams) to reach these populations (299).

ACIP recommends 1 dose of HepA vaccine during a hepatitis A outbreak for all unvaccinated persons aged ≥ 1 year who are at risk for HAV infection (e.g., persons who use injection or noninjection drugs, persons experiencing homelessness, and MSM) (12,300) or at risk for severe disease from HAV (e.g., persons with chronic liver disease and persons with HIV infection). A single dose of preexposure HepA vaccine has been shown to successfully control outbreaks of hepatitis A (246).

CDC Clinical Guidance

In the event of a community outbreak propagated by person-to-person transmission, public health officials should consider recommending administration of preexposure HepA vaccination in close congregate settings providing services to persons at high risk for infection (e.g., persons incarcerated in correctional facilities, health care settings for persons who use injection or noninjection drugs, homeless shelters, and syringe services programs) who are in the vicinity of the outbreak. Increased risk for HAV infection and therefore an increased risk for an outbreak exists in these settings (12,55,299,301). Congregate settings offer a unique opportunity to efficiently vaccinate during an outbreak, and expanded vaccination of populations at risk for infection during an outbreak has the

potential to halt transmission more quickly than nontargeted approaches (12).

Serologic Testing

Prevaccination

Prevaccination serologic testing for hepatitis A immunity before vaccination is not routinely recommended but may be considered in specific settings to reduce costs by not vaccinating persons who are already immune. Prevaccination serologic testing should not be a barrier to vaccination of susceptible persons, especially in populations that are difficult to access. If prevaccination serologic testing is performed, commercially available tests for total anti-HAV or IgG anti-HAV should be used.

Persons for whom prevaccination testing will likely be most cost-effective include adults who were either born in or lived for extensive periods in geographic areas with high or intermediate hepatitis A endemicity (Figure 3). Prevaccination serologic testing of children is not indicated because of the low prevalence of infection in this age group (9).

In populations that are expected to have high rates of previous HAV infection, vaccination history should be obtained when feasible before testing or vaccination. Vaccination should not be postponed if vaccination history cannot be obtained, if records are unavailable, or if prevaccination testing is not feasible. Vaccinating persons immune from natural infection carries no known risk, nor does giving extra doses of HepA vaccine (302).

Postvaccination

Serologic testing for immunity is not necessary after routine vaccination of infants, children, or adults. Testing for the presence of anti-HAV antibody after vaccination is recommended for persons whose subsequent clinical management depends on knowledge of their immune status and persons for whom revaccination might be indicated, such as persons with HIV infection and other immunocompromised persons (e.g., HCT and solid organ transplant recipients and persons receiving chemotherapy) (see Persons with HIV Infection; Revaccination).

Revaccination

Revaccination (i.e., booster dose, challenge dose, or revaccination with a complete series) is not recommended for healthy persons who were vaccinated with a complete series as infants, children, or adults (238,240,243). For immunocompromised persons (e.g., persons with HIV infection, HCT and solid organ transplant recipients, and persons receiving chemotherapy), limited data are available to determine the need for booster doses or revaccination with a complete series.

Clinicians may consider revaccinating persons with HIV infection (see Persons with HIV Infection) and persons who received HepA vaccine while immunosuppressed from chemotherapy who failed to demonstrate an adequate immune response (i.e., ≥ 10 mIU/mL) after the initial HepA vaccination series (146,205). In such cases, postvaccination serologic testing should be performed at least 1 month after revaccination with a complete vaccine series. If the response to revaccination is still not adequate (i.e., < 10 mIU/mL), additional vaccination is not recommended; however, the person should be counseled concerning methods to prevent HAV infection, including the need for IG after an exposure. If vaccination results in seroconversion, limited data exist on the need for repeat testing or on the frequency of booster doses or revaccination.

Interrupted Schedules and Minimum Dosing Intervals

- **Schedule interruption.** For all ages, when the HepA vaccine schedule is interrupted, the vaccine series does not need to be restarted. Limited data indicate that the response to a second dose delayed for 20–31 months in persons age > 2 years (Havrix) and delayed 4–8 years among adults (Havrix) was similar to that of the licensed schedules. Among adults, the response to a second dose delayed for 12–18 months (Vaqta) was similar to the response to a booster dose administered after 6 months (303–305).
- **First and second dose administered.** If the first and second doses of single-antigen HepA vaccine were administered < 6 months apart, then the second dose is invalid and should be repeated 6 months after the invalid second dose. However, if this repeat dose (the third dose) is administered any time ≥ 6 months after the first dose and at least the age-appropriate dose was administered, the series can be considered complete (205).
- **Minimum interval or age.** Vaccine doses administered ≤ 4 days before the minimum interval or age are considered valid. Because of the unique accelerated schedule for Twinrix, the 4-day guideline does not apply to the first 3 doses of this vaccine when administered on a 0-day, 7-day, 21–30-day, and 12-month schedule (306).

Other Vaccination Management Issues and Considerations

- **Dose and schedule.** HepA vaccines should only be administered with the age-appropriate dose and schedule. Administering 2 doses of 25 units of Vaqta or 2 doses of 720 ELISA units of Havrix at the same time or sequentially to persons aged ≥ 19 years instead of 1 adult dose is not recommended and is not included as a method for dosage and administration in the manufacturers' package inserts;

the package inserts for Havrix and Vaqta include additional information (202).

- **Twinrix and PEP.** Twinrix is not recommended for PEP.
- **Vaccine interchangeability.** ACIP prefers that doses of HepA vaccine in a series come from the same manufacturer; however, if this is not possible or if the manufacturer of doses given previously is unknown, providers should administer the vaccine that they have available (205). The dose should be considered valid and does not need to be repeated. No differences in immunogenicity have been observed when 1 valid dose of HepA vaccine produced by one manufacturer is followed by a dose from a different manufacturer, administered according to the recommended schedule (307,308); the package inserts for Vaqta include additional information (202).
 - Single-antigen HepA and HepB vaccines may be used in conjunction with Twinrix to form a complete series of these vaccines. Because the hepatitis B component of Twinrix is equivalent to a standard adult dose of HepB vaccine, the schedule is the same regardless of which vaccine is used for which dose. Because the hepatitis A component of Twinrix is equivalent to a pediatric dose of HepA vaccine, a series mixing the single-antigen HepA vaccine and Twinrix is more complex.
 - A person aged > 19 years who receives 1 dose of Twinrix can complete the HepA vaccine series with 2 doses of adult formulation HepA vaccine separated by at least 5 months. A person who receives 2 doses of Twinrix can complete the HepA vaccine series with 1 dose of adult formulation HepA vaccine or Twinrix 5 months after the second dose. A person aged ≥ 19 years who begins the hepatitis A series with single-antigen HepA vaccine may complete the series with 2 doses of Twinrix or 1 dose of adult formulation HepA vaccine. Persons who are aged 18 years should follow the same schedule as for adults, using the pediatric formulations of HepA vaccine. Providers should only accept dated records as evidence of HepA vaccination. Additional information on HepB vaccination is available (306). (The Twinrix package insert and related references provide more information on equivalent protection following the accelerated, alternate Twinrix schedule [202,283,309,310].)
- **Susceptible persons.** Vaccination should occur among susceptible persons (i.e., unvaccinated, partially vaccinated, nonresponders to vaccine or never infected).
- **Vaccine records.** Although vaccinations should not be postponed if records cannot be found, an attempt to locate missing records should be made by contacting previous health care personnel, reviewing state or local immunization information systems, or searching for a personally held

record. If records cannot be located within a reasonable time, these persons should be considered susceptible and vaccinated with the appropriate dose and schedule.

- **Vaccine series initiation.** In all settings, concern about loss to follow-up before HepA vaccine series completion should not be a deterrent to initiating the vaccine series in persons for whom HepA vaccination is recommended. Vaccination should be initiated even though completion of the series might not be ensured. One dose of HepA vaccine provides personal protection and can contribute to herd immunity, although long-term protection might be suboptimal (244).
- **Live vaccines and IG.** Live vaccines (e.g., MMR and varicella vaccines) should be administered at least 2 weeks before (205) or at least 6 months after the administration of IG (217); the GamaSTAN package insert includes additional information (205,217). If IG must be administered <2 weeks after the administration of MMR or varicella vaccine, the patient should be revaccinated no sooner than 6 months after receipt of IG unless serologic testing is feasible and indicates a response to that vaccine (205,217).
- **Vaccine and IG.** Persons administered IG for whom HepA vaccine is also recommended should receive a dose of vaccine simultaneously with IG in a different anatomic site (e.g., separate limbs). If only IG or only vaccine is available, either available product should be administered as soon as possible. The person may return for the other product when available, within 2 weeks of exposure if the product is administered as part of postexposure prophylaxis.
- **Standing orders.** Implementation of standing orders should be considered to overcome barriers and increase coverage.
- **Vaccine adverse events.** Adverse events occurring after administration of any vaccine should be reported to VAERS. Reports can be submitted to VAERS online, by fax, or by mail. More information about VAERS is available by telephone (800-822-7967) and online (<https://vaers.hhs.gov>).

Future Directions

ACIP and CDC will review these recommendations as new epidemiology or other information related to HepA vaccines (including licensure of additional hepatitis A-containing vaccines), HepA vaccine adverse events, and the experience gained in the implementation of these recommendations becomes available. Revised recommendations will be developed as needed.

Acknowledgments

Art Reingold, School of Public Health, University of California, Berkeley; Doug Campos-Outcalt, University of Arizona, Phoenix; Jessica MacNeil, Office of the Director, National Center for Immunization and Respiratory Diseases, CDC; Immunization Safety Office, Division of Healthcare Quality Promotion, CDC.

Members of the Advisory Committee on Immunization Practices (member roster for June 2019 is available at <https://www.cdc.gov/vaccines/acip/members/index.html>).

References

1. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. *Am J Epidemiol* 1985;122:226–33. <https://doi.org/10.1093/oxfordjournals.aje.a114093>
2. Kemmer NM, Miskovsky EP. Hepatitis A. *Infect Dis Clin North Am* 2000;14:605–15. [https://doi.org/10.1016/S0891-5520\(05\)70123-9](https://doi.org/10.1016/S0891-5520(05)70123-9)
3. Keeffe E. Hepatitis A in patients with chronic liver disease - severity of illness and prevention with vaccination. *J Viral Hepat* 2000;7(Suppl 1):15–7. <https://doi.org/10.1046/j.1365-2893.2000.00016.x>
4. Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014;58:309–18. <https://doi.org/10.1093/cid/cit816>
5. Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A. Review of 14 cases and literature survey. *Medicine (Baltimore)* 1992;71:14–23. <https://doi.org/10.1097/00005792-199201000-00002>
6. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. *MMWR Recomm Rep* 1996;45(No. RR-13).
7. CDC. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 1999;48(No. RR-12).
8. Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2006;55(No. RR-7).
9. CDC. Surveillance for viral hepatitis—United States, 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. <https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm>
10. Collier MG, Khudyakov YE, Selvage D, et al; Hepatitis A Outbreak Investigation Team. Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: an epidemiological case study. *Lancet Infect Dis* 2014;14:976–81. [https://doi.org/10.1016/S1473-3099\(14\)70883-7](https://doi.org/10.1016/S1473-3099(14)70883-7)
11. Viray MA, Hofmeister MG, Johnston DI, et al. Public health investigation and response to a hepatitis A outbreak from imported scallops consumed raw—Hawaii, 2016. *Epidemiol Infect* 2018;147:1–8.
12. Foster M, Ramachandran S, Myatt K, et al. Hepatitis A virus outbreaks associated with drug use and homelessness—California, Kentucky, Michigan, and Utah, 2017. *MMWR Morb Mortal Wkly Rep* 2018;67:1208–10. <https://doi.org/10.15585/mmwr.mm6743a3>
13. Yin S, Barker L, Ly KN, et al. Susceptibility to hepatitis A virus infection in the United States, 2007–2016. *Clin Infect Dis* 2020;ciaa298. <https://doi.org/10.1093/cid/ciaa298>
14. CDC. Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. <https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html#box2>

15. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. *MMWR Morb Mortal Wkly Rep* 2019;68:153–6. <https://doi.org/10.15585/mmwr.mm6806a6>
16. CDC; Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. *MMWR Morb Mortal Wkly Rep* 2009;58:1006–7.
17. Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. *MMWR Morb Mortal Wkly Rep* 2018;67:1216–20. <https://doi.org/10.15585/mmwr.mm6743a5>
18. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine* 2015;33:4398–405. <https://doi.org/10.1016/j.vaccine.2015.07.035>
19. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. *MMWR Surveill Summ* 2003;52(No. SS-1).
20. McNeil MM, Gee J, Weintraub ES, et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. *Vaccine* 2014;32:5390–8. <https://doi.org/10.1016/j.vaccine.2014.07.073>
21. Hill HA, Singleton JA, Yankey D, Elam-Evans LD, Pingali SC, Kang Y. Vaccination coverage by age 24 months among children born in 2015 and 2016—National Immunization Survey—Child, United States, 2016–2018. *MMWR Morb Mortal Wkly Rep* 2019;68:913–8. <https://doi.org/10.15585/mmwr.mm6841e2>
22. CDC. Atlanta, GA: US Department of Health and Human Services. Widespread person-to-person outbreaks of hepatitis A across the United States. <https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm>
23. Latash J, Dorsinville M, Del Rosso P, et al. Notes from the field: increase in reported hepatitis A infections among men who have sex with men—New York City, January–August 2017. *MMWR Morb Mortal Wkly Rep* 2017;66:999–1000. <https://doi.org/10.15585/mmwr.mm6637a7>
24. National Institutes of Health, National Institute on Drug Abuse. Substance use in women. Bethesda, MD: National Institutes of Health, National Institute on Drug Abuse; 2018. <https://www.drugabuse.gov/publications/research-reports/substance-use-in-women/summary>
25. Melnick JL. Properties and classification of hepatitis A virus. *Vaccine* 1992;10(Suppl 1):S24–6. [https://doi.org/10.1016/0264-410X\(92\)90536-S](https://doi.org/10.1016/0264-410X(92)90536-S)
26. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. *Hepatology* 2006;43(Suppl 1):S164–72. <https://doi.org/10.1002/hep.21052>
27. Zell R, Delwart E, Gorbalenya AE, et al; Ictv Report Consortium. ICTV virus taxonomy profile: *Picornaviridae*. *J Gen Virol* 2017;98:2421–2. <https://doi.org/10.1099/jgv.0.000911>
28. Cohen JI. Hepatitis A virus: insights from molecular biology. *Hepatology* 1989;9:889–95. <https://doi.org/10.1002/hep.1840090617>
29. Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. *J Hepatol* 2017;S0168–8278(17)32278–X.
30. Robertson BH, Jansen RW, Khanna B, et al. Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. *J Gen Virol* 1992;73:1365–77. <https://doi.org/10.1099/0022-1317-73-6-1365>
31. Costa-Mattioli M, Napoli AD, Ferré V, Billaudel S, Perez-Bercoff R, Cristina J. Genetic variability of hepatitis A virus. *J Gen Virol* 2003;84:3191–201. <https://doi.org/10.1099/vir.0.19532-0>
32. Vaughan G, Goncalves Rossi LM, Forbi JC, et al. Hepatitis A virus: host interactions, molecular epidemiology and evolution. *Infect Genet Evol* 2014;21:227–43. <https://doi.org/10.1016/j.meegid.2013.10.023>
33. Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, Purcell RH. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. *J Infect Dis* 1986;154:231–7. <https://doi.org/10.1093/infdis/154.2.231>
34. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide outbreak of hepatitis A. *Epidemiol Infect* 1997;118:243–52. <https://doi.org/10.1017/S0950268897007462>
35. Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. *Pediatrics* 2000;106:e54. <https://doi.org/10.1542/peds.106.4.e54>
36. Fiore AE. Hepatitis A transmitted by food. *Clin Infect Dis* 2004;38:705–15. <https://doi.org/10.1086/381671>
37. Barrett CE, Pape BJ, Benedict KM, et al. Impact of public health interventions on drinking water-associated outbreaks of hepatitis A—United States, 1971–2017. *MMWR Morb Mortal Wkly Rep* 2019;68:766–70. <https://doi.org/10.15585/mmwr.mm6835a4>
38. McCaustland KA, Bond WW, Bradley DW, Ebert JW, Maynard JE. Survival of hepatitis A virus in feces after drying and storage for 1 month. *J Clin Microbiol* 1982;16:957–8. <https://doi.org/10.1128/JCM.16.5.957-958.1982>
39. Niu MT, Polish LB, Robertson BH, et al. Multistate outbreak of hepatitis A associated with frozen strawberries. *J Infect Dis* 1992;166:518–24. <https://doi.org/10.1093/infdis/166.3.518>
40. Nordic Outbreak Investigation Team. Joint analysis by the Nordic countries of a hepatitis A outbreak, October 2012 to June 2013: frozen strawberries suspected. *Euro Surveill* 2013;18:20520. <https://doi.org/10.2807/1560-7917.ES2013.18.27.20520>
41. Reid TM, Robinson HG. Frozen raspberries and hepatitis A. *Epidemiol Infect* 1987;98:109–12. <https://doi.org/10.1017/S095026880006177X>
42. Favero MSBW. Disinfection and sterilization. In: Zuckerman AJ TH, ed. *Viral hepatitis, scientific basis and clinical management*. New York: Churchill Livingstone; 1993. pp. 565–75.
43. Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. *Vox Sang* 1994;67(Suppl 4):19–23, discussion 24–6. <https://doi.org/10.1159/000462759>
44. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. *Transfusion* 1998;38:573–9. <https://doi.org/10.1046/j.1537-2995.1998.38698326337.x>
45. Benjamin RJ. Nucleic acid testing: update and applications. *Semin Hematol* 2001;38(Suppl 9):11–6. [https://doi.org/10.1016/S0037-1963\(01\)90132-5](https://doi.org/10.1016/S0037-1963(01)90132-5)
46. Cohen JI, Feinstone S, Purcell RH. Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs. *J Infect Dis* 1989;160:887–90. <https://doi.org/10.1093/infdis/160.5.887>
47. Parry JV, Perry KR, Panday S, Mortimer PP. Diagnosis of hepatitis A and B by testing saliva. *J Med Virol* 1989;28:255–60. <https://doi.org/10.1002/jmv.1890280410>
48. Mackiewicz V, Dussaix E, Le Petitcorps ME, Roque-Afonso AM. Detection of hepatitis A virus RNA in saliva. *J Clin Microbiol* 2004;42:4329–31. <https://doi.org/10.1128/JCM.42.9.4329-4331.2004>
49. Krugman S, Giles JP. Viral hepatitis. New light on an old disease. *JAMA* 1970;212:1019–29. <https://doi.org/10.1001/jama.1970.03170190035005>
50. Lemon SM. Type A viral hepatitis. New developments in an old disease. *N Engl J Med* 1985;313:1059–67. <https://doi.org/10.1056/NEJM198510243131706>
51. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. *N Engl J Med* 1980;302:1222–7. <https://doi.org/10.1056/NEJM198005293022203>

52. Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. *J Infect Dis* 1995;171(Suppl 1):S15–8. https://doi.org/10.1093/infdis/171.Supplement_1.S15
53. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. *Vaccine* 1992;10(Suppl 1):S15–7. [https://doi.org/10.1016/0264-410X\(92\)90533-P](https://doi.org/10.1016/0264-410X(92)90533-P)
54. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. *Ann Intern Med* 1987;106:221–6. <https://doi.org/10.7326/0003-4819-106-2-221>
55. Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections—United States, 2013–2018. *MMWR Morb Mortal Wkly Rep* 2019;68:413–5. <https://doi.org/10.15585/mmwr.mm6818a2>
56. Robertson BH, Averhoff F, Cromeans TL, et al. Genetic relatedness of hepatitis A virus isolates during a community-wide outbreak. *J Med Virol* 2000;62:144–50. [https://doi.org/10.1002/1096-9071\(200010\)62:2<144::AID-JMV4>3.0.CO;2-I](https://doi.org/10.1002/1096-9071(200010)62:2<144::AID-JMV4>3.0.CO;2-I)
57. Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. *J Infect Dis* 1991;164:476–82. <https://doi.org/10.1093/infdis/164.3.476>
58. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. *J Infect Dis* 2000;182:12–7. <https://doi.org/10.1086/315701>
59. Tjon GM, Coutinho RA, van den Hoek A, et al. High and persistent excretion of hepatitis A virus in immunocompetent patients. *J Med Virol* 2006;78:1398–405. <https://doi.org/10.1002/jmv.20711>
60. Costa-Mattioli M, Allavena C, Poirier AS, Billaudel S, Raffi F, Ferré V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. *J Med Virol* 2002;68:7–11. <https://doi.org/10.1002/jmv.10163>
61. Foster MA, Weil LM, Jin S, et al. Transmission of hepatitis A virus through combined liver-small intestine-pancreas transplantation. *Emerg Infect Dis* 2017;23:590–6. <https://doi.org/10.3201/eid2304.161532>
62. Liaw YF, Yang CY, Chu CM, Huang MJ. Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak. *Infection* 1986;14:156–8. <https://doi.org/10.1007/BF01645253>
63. Lemon SM, Murphy PC, Provost PJ, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. *J Infect Dis* 1997;176:9–19. <https://doi.org/10.1086/514044>
64. American Medical Association; American Nurses Association–American Nurses Foundation; CDC; Center for Food Safety and Applied Nutrition, Food and Drug Administration; Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. *MMWR Recomm Rep* 2004;53(No. RR-4).
65. Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. *Hepatology* 1984;4:933–6. <https://doi.org/10.1002/hep.1840040525>
66. Sikuler E, Keynan A, Hanuka N, Zagron-Bachir G, Sarov I. Persistence of a positive test for IgM antibodies to hepatitis A virus in late convalescent sera. *Isr J Med Sci* 1987;23:193–5.
67. CDC. Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002–2004. *MMWR Morb Mortal Wkly Rep* 2005;54:453–6.
68. Castrodale L, Fiore A, Schmidt T. Detection of immunoglobulin M antibody to hepatitis A virus in Alaska residents without other evidence of hepatitis. *Clin Infect Dis* 2005;41:e86–8. <https://doi.org/10.1086/497073>
69. Decker RH, Overby LR, Ling CM, Frösner G, Deinhardt F, Boggs J. Serologic studies of transmission of hepatitis A in humans. *J Infect Dis* 1979;139:74–82. <https://doi.org/10.1093/infdis/139.1.74>
70. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. *J Infect Dis* 1983;148:1033–9. <https://doi.org/10.1093/infdis/148.6.1033>
71. Locarnini SA, Ferris AA, Lehmann NI, Gust ID. The antibody response following hepatitis A infection. *Intervirology* 1977;8:309–18. <https://doi.org/10.1159/000148905>
72. Stapleton JT. Host immune response to hepatitis A virus. *J Infect Dis* 1995;171(Suppl 1):S9–14. https://doi.org/10.1093/infdis/171.Supplement_1.S9
73. Amon JJ, Devasia R, Xia G, et al. Molecular epidemiology of foodborne hepatitis A outbreaks in the United States, 2003. *J Infect Dis* 2005;192:1323–30. <https://doi.org/10.1086/462425>
74. Nainan OV, Armstrong GL, Han XH, Williams I, Bell BP, Margolis HS. Hepatitis A molecular epidemiology in the United States, 1996–1997: sources of infection and implications of vaccination policy. *J Infect Dis* 2005;191:957–63. <https://doi.org/10.1086/427992>
75. Hutin YJ, Pool V, Cramer EH, et al; National Hepatitis A Investigation Team. A multistate, foodborne outbreak of hepatitis A. *N Engl J Med* 1999;340:595–602. <https://doi.org/10.1056/NEJM199902253400802>
76. Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. *Clin Microbiol Rev* 2006;19:63–79. <https://doi.org/10.1128/CMR.19.1.63-79.2006>
77. Funkhouser AW, Purcell RH, D’Hondt E, Emerson SU. Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. *J Virol* 1994;68:148–57. <https://doi.org/10.1128/JVI.68.1.148-157.1994>
78. Cohen JI, Rosenblum B, Feinstone SM, Ticehurst J, Purcell RH. Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. *J Virol* 1989;63:5364–70. <https://doi.org/10.1128/JVI.63.12.5364-5370.1989>
79. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. *JAMA* 1994;272:885–9. <https://doi.org/10.1001/jama.1994.03520110065031>
80. Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus. *Cold Spring Harb Perspect Med* 2018;8:a031716. <https://doi.org/10.1101/cshperspect.a031716>
81. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. *Int J Health Geogr* 2011;10:57. <https://doi.org/10.1186/1476-072X-10-57>
82. Nelson N. Hepatitis A. CDC yellow book 2020. New York, NY: Oxford University Press; 2020.
83. Cotter SM, Sansom S, Long T, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. *J Infect Dis* 2003;187:1235–40. <https://doi.org/10.1086/374057>
84. Regan DG, Wood JG, Benevent C, et al. Estimating the critical immunity threshold for preventing hepatitis A outbreaks in men who have sex with men. *Epidemiol Infect* 2016;144:1528–37. <https://doi.org/10.1017/S0950268815002605>
85. European Centre for Disease Prevention and Control. Hepatitis A outbreaks in the EU/EEA mostly affecting men who have sex with men—third update. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2017. <https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-hepatitis-outbreak-eueea-mostly-affecting-men-who-have-sex>
86. Ndumbi P, Freidl GS, Williams CJ, et al. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. *Euro Surveill* 2018;23:08.
87. Plunkett J, Mandal S, Balogun K, et al. Hepatitis A outbreak among men who have sex with men (MSM) in England, 2016–2018: the contribution of past and current vaccination policy and practice. *Vaccine X* 2019;1:100014.

88. European Centre for Disease Prevention and Control. Epidemiological update: hepatitis A outbreak in the EU/EEA mostly affecting men who have sex with men. Stockholm, Sweden: European Centre for Disease Prevention and Control; 2017. <https://www.ecdc.europa.eu/en/news-events/epidemiological-update-hepatitis-outbreak-eueea-mostly-affecting-men-who-have-sex-men-2>
89. Gozlan Y, Bar-Or I, Rakovsky A, et al. Ongoing hepatitis A among men who have sex with men (MSM) linked to outbreaks in Europe in Tel Aviv area, Israel, December 2016 - June 2017. *Euro Surveill* 2017;22:30575. <https://doi.org/10.2807/1560-7917.ES.2017.22.29.30575>
90. Rivas V, Barrera A, Pino K, et al. Hepatitis A outbreak since November 2016 affecting men who have sex with men (MSM) in Chile connected to the current outbreak in MSM in Europe, situation up to October 2017. *Euro Surveill* 2018;23.
91. Tanaka S, Kishi T, Ishihara A, et al. Outbreak of hepatitis A linked to European outbreaks among men who have sex with men in Osaka, Japan, from March to July 2018. *Hepatology* 2019;49:705–10. <https://doi.org/10.1111/hepr.13314>
92. Srivastav A, O'Halloran A, Lu PJ, Williams WW, Hutchins SS. Vaccination differences among U.S. adults by their self-identified sexual orientation, National Health Interview Survey, 2013–2015. *PLoS One* 2019;14:e0213431. <https://doi.org/10.1371/journal.pone.0213431>
93. Whitehead J, Shaver J, Stephenson R. Outness, stigma, and primary health care utilization among rural LGBT populations. *PLoS One* 2016;11:e0146139. <https://doi.org/10.1371/journal.pone.0146139>
94. Bialek SR, Barry V, Bell BP, et al; Young Men's Survey Study Group. Seroprevalence and correlates of hepatitis A among HIV-negative American men who have sex with men. *Sex Health* 2011;8:343–8. <https://doi.org/10.1071/SH10162>
95. Siconolfi DE, Halkitis PN, Rogers ME. Hepatitis vaccination and infection among gay, bisexual, and other men who have sex with men who attend gyms in New York City. *Am J Men Health* 2009;3:141–9. <https://doi.org/10.1177/1557988308315151>
96. Vong S, Fiore AE, Haight DO, et al. Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users. *Vaccine* 2005;23:1021–8. <https://doi.org/10.1016/j.vaccine.2004.07.038>
97. Lugoboni F, Pajusko B, Albiero A, Quaglio G. Hepatitis A virus among drug users and the role of vaccination: a review. *Front Psychiatry* 2012;2:79. <https://doi.org/10.3389/fpsy.2011.00079>
98. Hutin YJ, Sabin KM, Hutwagner LC, et al. Multiple modes of hepatitis A virus transmission among methamphetamine users. *Am J Epidemiol* 2000;152:186–92. <https://doi.org/10.1093/aje/152.2.186>
99. Collier MG, Drobeniuc J, Cuevas-Mota J, Garfein RS, Kamili S, Teshale EH. Hepatitis A and B among young persons who inject drugs—vaccination, past, and present infection. *Vaccine* 2015;33:2808–12. <https://doi.org/10.1016/j.vaccine.2015.04.019>
100. Koepke R, Sill DN, Akhtar WZ, et al. Hepatitis A and hepatitis B vaccination coverage among persons who inject drugs and have evidence of hepatitis C infection. *Public Health Rep* 2019;134:651–9. <https://doi.org/10.1177/0033354919874088>
101. Hinthorn DR, Foster MT Jr, Bruce HL, Aach RD. An outbreak of chimpanzee associated hepatitis. *J Occup Med* 1974;16:388–91.
102. Dienstag JL, Davenport FM, McCollum RW, Hennessy AV, Klatskin G, Purcell RH. Nonhuman primate-associated viral hepatitis type A. Serologic evidence of hepatitis A virus infection. *JAMA* 1976;236:462–4. <https://doi.org/10.1001/jama.1976.03270050018021>
103. Robertson BH. Viral hepatitis and primates: historical and molecular analysis of human and nonhuman primate hepatitis A, B, and the GB-related viruses. *J Viral Hepat* 2001;8:233–42. <https://doi.org/10.1046/j.1365-2893.2001.00295.x>
104. Advisory Committee on Immunization Practices; CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60(No. RR-7).
105. Raabe VN, Sautter C, Chesney M, Eckerle JK, Howard CR, John CC. Hepatitis A screening for internationally adopted children from hepatitis A endemic countries. *Clin Pediatr (Phila)* 2014;53:31–7. <https://doi.org/10.1177/000922813505903>
106. Fischer GE, Teshale EH, Miller C, et al. Hepatitis A among international adoptees and their contacts. *Clin Infect Dis* 2008;47:812–4. <https://doi.org/10.1086/591199>
107. Pelletier AR, Mehta PJ, Burgess DR, et al. An outbreak of hepatitis A among primary and secondary contacts of an international adoptee. *Public Health Rep* 2010;125:642–6. <https://doi.org/10.1177/003335491012500505>
108. Sweet K, Sutherland W, Ehresmann K, Lynfield R. Hepatitis A infection in recent international adoptees and their contacts in Minnesota, 2007–2009. *Pediatrics* 2011;128:e333–8. <https://doi.org/10.1542/peds.2010-1840>
109. Vernon JA, Payette M, Chatterjee A. Social welfare and adolescent vaccination programs in the United States: the economic opportunities for a systematic expansion. *Soc Work Public Health* 2009;24:414–45. <https://doi.org/10.1080/19371910903038165>
110. Wilson ME, Kimble J. Posttravel hepatitis A: probable acquisition from an asymptomatic adopted child. *Clin Infect Dis* 2001;33:1083–5. <https://doi.org/10.1086/323200>
111. CDC. Viral hepatitis surveillance—United States, 2009. Atlanta, GA: US Department of Health and Human Services. <https://www.cdc.gov/hepatitis/statistics/2009surveillance/index.htm>
112. National Health Care for the Homeless Council [Internet]. Understanding homelessness: frequently asked questions. Nashville, TN: National Health Care for the Homeless Council. <https://nhhc.org/understanding-homelessness/faq/>
113. Health Centers, 42 U.S.C. Sect. 254b. https://www.law.cornell.edu/uscode/text/42/254b#tab_default_2
114. Health Resources and Services Administration, Bureau of Primary Health Care. Health center program compliance manual. Glossary: 330(h) homeless population. Rockville, MD: Health Resources and Services Administration. <https://bphc.hrsa.gov/programrequirements/compliancemanual/glossary.html>
115. Doran KM, Rahai N, McCormack RP, et al. Substance use and homelessness among emergency department patients. *Drug Alcohol Depend* 2018;188:328–33. <https://doi.org/10.1016/j.drugalcdep.2018.04.021>
116. DeGroot NP, Mattson CL, Tie Y, Brooks JT, Garg S, Weiser J. Hepatitis A virus immunity and vaccination among at-risk persons receiving HIV medical care. *Prev Med Rep* 2018;11:139–44. <https://doi.org/10.1016/j.pmedr.2018.06.006>
117. Moon AM, Lowy E, Maier MM, et al. Hepatitis A virus prevention and vaccination within and outside the Veterans Health Administration in light of recent outbreaks. *Fed Pract* 2018;35(Suppl 2):S32–7.
118. Sun HY, Kung HC, Ho YC, et al. Seroprevalence of hepatitis A virus infection in persons with HIV infection in Taiwan: implications for hepatitis A vaccination. *Int J Infect Dis* 2009;13:e199–205. <https://doi.org/10.1016/j.ijid.2008.12.009>
119. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. *J Viral Hepat* 2007;14:189–93. <https://doi.org/10.1111/j.1365-2893.2006.00822.x>
120. Sheth AN, Moore RD, Gebo KA. Provision of general and HIV-specific health maintenance in middle aged and older patients in an urban HIV clinic. *AIDS Patient Care STDS* 2006;20:318–25. <https://doi.org/10.1089/apc.2006.20.318>
121. CDC. Medical monitoring project. US Department of Health and Human Services, CDC. <https://www.cdc.gov/hiv/statistics/systems/mmp/resources.html>

122. Adejumo A, Sivapalan V, Mannheimer S. An assessment of the seroprevalence of hepatitis A antibody and vaccination among HIV patients in an inner city HIV clinic. *Int J Infect Dis* 2010;14:e404. <https://doi.org/10.1016/j.ijid.2010.02.518>
123. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. *N Engl J Med* 2007;356:1445–54. <https://doi.org/10.1056/NEJMra065142>
124. Lin KY, Chen GJ, Lee YL, et al. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review. *World J Gastroenterol* 2017;23:3589–606. <https://doi.org/10.3748/wjg.v23.i20.3589>
125. Ciccullo A, Gagliardini R, Baldin G, et al. An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. *HIV Med* 2018;19:369–75. <https://doi.org/10.1111/hiv.12597>
126. Comelli A, Izzo I, Casari S, Spinetti A, Bergamasco A, Castelli F. Hepatitis A outbreak in men who have sex with men (MSM) in Brescia (Northern Italy), July 2016–July 2017. *Infez Med* 2018;26:46–51.
127. Fonquernie L, Meynard JL, Charrois A, Delamare C, Meyohas MC, Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. *Clin Infect Dis* 2001;32:297–9. <https://doi.org/10.1086/318478>
128. Gallego M, Robles M, Palacios R, et al. Impact of acute hepatitis A virus (HAV) infection on HIV viral load in HIV-infected patients and influence of HIV infection on acute HAV infection. *J Int Assoc Physicians AIDS Care (Chic)* 2011;10:40–2. <https://doi.org/10.1177/1545109710385692>
129. Ida S, Tachikawa N, Nakajima A, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. *Clin Infect Dis* 2002;34:379–85. <https://doi.org/10.1086/338152>
130. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. *Am J Med* 2005;118(Suppl 10A):75S–83S. <https://doi.org/10.1016/j.amjmed.2005.07.024>
131. Lee YL, Chen GJ, Chen NY, et al; Taiwan HIV Study Group. Less severe but prolonged course of acute hepatitis A in human immunodeficiency virus (HIV)-infected patients compared with HIV-uninfected patients during an outbreak: a multicenter observational study. *Clin Infect Dis* 2018;67:1595–602. <https://doi.org/10.1093/cid/ciy328>
132. Lombardi A, Rossotti R, Moiola MC, et al. The impact of HIV infection and men who have sex with men status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009–2016 period. *J Viral Hepat* 2019;26:761–5. <https://doi.org/10.1111/jvh.13082>
133. Puoti M, Moiola MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. *Semin Liver Dis* 2012;32:103–13. <https://doi.org/10.1055/s-0032-1316473>
134. Yotsuyanagi H, Koike K, Yasuda K, et al. Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. *Hepatology* 1996;24:10–3. <https://doi.org/10.1002/hep.510240103>
135. Mena G, García-Basteiro AL, Llupia A, et al. Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. *Vaccine* 2013;31:3668–74. <https://doi.org/10.1016/j.vaccine.2013.06.012>
136. Mena G, Vilajeliu A, Urbiztondo L, Bayas JM. [Regional recommendations on hepatitis vaccination in human immunodeficiency virus infected adult patients in Spain: Evidence-based disparity?] *Med Clin (Barc)* 2015;145:163–70. <https://doi.org/10.1016/j.medcli.2014.12.023>
137. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. *Expert Rev Vaccines* 2002;1:9–23. <https://doi.org/10.1586/14760584.1.1.9>
138. Phung BC, Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. *Hum Vaccin Immunother* 2012;8:554–9. <https://doi.org/10.4161/hv.19105>
139. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. *Clin Infect Dis* 2004;39:1207–13. <https://doi.org/10.1086/424666>
140. Dlamini SK, Madhi SA, Muloiwa R, et al. Guidelines for the vaccination of HIV-infected adolescents and adults in South Africa. *South Afr J HIV Med* 2018;19:8. <https://doi.org/10.4102/sajhivmed.v19i1.839>
141. Kemper CA, Haubrich R, Frank I, et al; California Collaborative Treatment Group. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. *J Infect Dis* 2003;187:1327–31. <https://doi.org/10.1086/374562>
142. Shire NJ, Sherman KE. Vaccination against hepatitis A and B in patients with HIV. *Curr Hepat Rep* 2006;5:63–7. <https://doi.org/10.1007/s11901-006-0006-z>
143. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. *AIDS Patient Care STDS* 2014;28:397–410. <https://doi.org/10.1089/apc.2014.0121>
144. Van Damme P, Banatvala J, Fay O, et al; International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? *Lancet* 2003;362:1065–71. [https://doi.org/10.1016/S0140-6736\(03\)14418-2](https://doi.org/10.1016/S0140-6736(03)14418-2)
145. Crum-Cianflone NF, Wilkins K, Lee AW, et al; Infectious Disease Clinical Research Program HIV Working Group. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. *J Infect Dis* 2011;203:1815–23. <https://doi.org/10.1093/infdis/jir180>
146. Huang SH, Huang CH, Wang NC, et al; Taiwan HIV Study Group. Early seroreversion after 2 doses of hepatitis A vaccination in human immunodeficiency virus-positive patients: incidence and associated factors. *Hepatology* 2019;70:465–75. <https://doi.org/10.1002/hep.30495>
147. Armstrong KE, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC. Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002–2007. *J Int Assoc Physicians AIDS Care (Chic)* 2010;9:179–86. <https://doi.org/10.1177/1545109710368721>
148. Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? *J Viral Hepat* 2000;7(Suppl 1):1–3. <https://doi.org/10.1046/j.1365-2893.2000.00021.x>
149. Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. *Can J Public Health* 2000;91:168–70. <https://doi.org/10.1007/BF03404264>
150. Pramoolsinsap C. Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand. *J Viral Hepat* 2000;7(Suppl 1):11–2. <https://doi.org/10.1046/j.1365-2893.2000.00017.x>
151. Reiss G, Keeffe EB. Hepatitis vaccination in patients with chronic liver disease. *Aliment Pharmacol Ther* 2004;19:715–27. <https://doi.org/10.1111/j.1365-2036.2004.01906.x>
152. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *J Viral Hepat* 2000;7(Suppl 1):7–8. <https://doi.org/10.1046/j.1365-2893.2000.00019.x>
153. Collier MG, Tong X, Xu F. Hepatitis A hospitalizations in the United States, 2002–2011. *Hepatology* 2015;61:481–5. <https://doi.org/10.1002/hep.27537>
154. Szmunes W, Purcell RH, Dienstag JL, Stevens CE. Antibody to hepatitis A antigen in institutionalized mentally retarded patients. *JAMA* 1977;237:1702–5. <https://doi.org/10.1001/jama.1977.03270430044016>

155. Bohm SR, Berger KW, Hackert PB, et al. Hepatitis A outbreak among adults with developmental disabilities in group homes—Michigan, 2013. *MMWR Morb Mortal Wkly Rep* 2015;64:148–52.
156. Lim HS, Choi K, Lee S. Epidemiological investigation of an outbreak of hepatitis A at a residential facility for the disabled, 2011. *J Prev Med Public Health* 2013;46:62–73. <https://doi.org/10.3961/jpmph.2013.46.2.62>
157. Knopf-Amelung S. Incarceration and homelessness: a revolving door of risk. In *Focus: A Quarterly Research Review of the National Health Care for the Homeless Council* 2013;2:5. https://nhhc.org/wp-content/uploads/2019/08/infocus_incarceration_nov2013.pdf
158. Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics; 2006.
159. Skidmore S, Parry JV, Nottage P. An investigation of the potential risk of an HAV outbreak in a prison population following the introduction of cases from a community outbreak. *Commun Dis Public Health* 2001;4:133–5.
160. Whiteman D, McCall B, Falconer A. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. *J Viral Hepat* 1998;5:277–83. <https://doi.org/10.1046/j.1365-2893.1998.00107.x>
161. Gilbert RL, O'Connor T, Mathew S, Allen K, Piper M, Gill ON. Hepatitis A vaccination—a prison-based solution for a community-based outbreak? *Commun Dis Public Health* 2004;7:289–93.
162. Safran R. Hepatitis A/B prevention at Washington State Penitentiary. *J Investig Med* 2010;58:242–3.
163. Costumbrado J, Stirland A, Cox G, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. *Vaccine* 2012;30:6878–82. <https://doi.org/10.1016/j.vaccine.2012.09.006>
164. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. *Transfusion* 1999;39:1160–8. <https://doi.org/10.1046/j.1537-2995.1999.39111160.x>
165. Mannucci PM, Gdovin S, Gringeri A, et al; The Italian Collaborative Group. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. *Ann Intern Med* 1994;120:1–7. <https://doi.org/10.7326/0003-4819-120-1-199401010-00001>
166. US Food and Drug Administration. Guide to inspections of viral clearance processes for plasma derivatives. Silver Spring, MD: US Food and Drug Administration; 2008. <https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB98137144.xhtml>
167. Gröner A. Pathogen safety of plasma-derived products - Haemate P/Humate-P. *Haemophilia* 2008;14(Suppl 5):54–71. <https://doi.org/10.1111/j.1365-2516.2008.01852.x>
168. Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. *Transfusion* 2014;54:1406–17. <https://doi.org/10.1111/trf.12423>
169. CDC. 2016—Multistate outbreak of hepatitis A linked to frozen strawberries (final update). Atlanta, GA: US Department of Health and Human Services, CDC; 2016. <https://www.cdc.gov/hepatitis/outbreaks/2016/hav-strawberries.htm>
170. Ridpath A, Reddy V, Layton M, et al. Hepatitis A cases among food handlers: a local health department response—New York City, 2013. *J Public Health Manag Pract* 2017;23:571–6. <https://doi.org/10.1097/PHH.0000000000000526>
171. Sharapov UM, Kentenyants K, Groeger J, Roberts H, Holmberg SD, Collier MG. Hepatitis A infections among food handlers in the United States, 1993–2011. *Public Health Rep* 2016;131:26–9. <https://doi.org/10.1177/003335491613100107>
172. Morey RJ, Collier MG, Nelson NP. The financial burden of public health responses to hepatitis A cases among food handlers, 2012–2014. *Public Health Rep* 2017;132:443–7. <https://doi.org/10.1177/0033354917710947>
173. Hofmeister MG, Foster MA, Montgomery MP, Gupta N. Notes from the field: assessing the role of food handlers in hepatitis A virus transmission—multiple states, 2016–2019. *MMWR Morb Mortal Wkly Rep* 2020;69(20):636–37. <https://doi.org/10.15585/mmwr.mm6920a4>
174. Hadler SC, Erben JJ, Francis DP, Webster HM, Maynard JE. Risk factors for hepatitis A in day-care centers. *J Infect Dis* 1982;145:255–61. <https://doi.org/10.1093/infdis/145.2.255>
175. Kuhar DT, Carrico RM, Cox K, et al. Infection control in healthcare personnel: infrastructure and routine practices for occupational infection prevention and control services. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. <https://www.cdc.gov/infectioncontrol/pdf/guidelines/infection-control-HCP-H.pdf>
176. Klein BS, Michaels JA, Rytel MW, Berg KG, Davis JP. Nosocomial hepatitis A. A multinursery outbreak in Wisconsin. *JAMA* 1984;252:2716–21. <https://doi.org/10.1001/jama.1984.03350190018012>
177. Noble RC, Kane MA, Reeves SA, Roeckel I. Posttransfusion hepatitis A in a neonatal intensive care unit. *JAMA* 1984;252:2711–5. <https://doi.org/10.1001/jama.1984.03350190013011>
178. Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis A among health care workers: risk factors for transmission. *Am J Public Health* 1993;83:1679–84. <https://doi.org/10.2105/AJPH.83.12.1679>
179. Goodman RA. Nosocomial hepatitis A. *Ann Intern Med* 1985;103:452–4. <https://doi.org/10.7326/0003-4819-103-3-452>
180. Papaevangelou GJ, Roumeliotou-Karayannis AJ, Contoyannis PC. The risk of nosocomial hepatitis A and B virus infections from patients under care without isolation precaution. *J Med Virol* 1981;7:143–8. <https://doi.org/10.1002/jmv.1890070208>
181. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. *Am J Infect Control* 2007;35(Suppl 2):S65–164. <https://doi.org/10.1016/j.ajic.2007.10.007>
182. Glas C, Hotz P, Steffen R. Hepatitis A in workers exposed to sewage: a systematic review. *Occup Environ Med* 2001;58:762–8. <https://doi.org/10.1136/oem.58.12.762>
183. Lerman Y, Chodik G, Aloni H, Ribak J, Ashkenazi S. Occupations at increased risk of hepatitis A: a 2-year nationwide historical prospective study. *Am J Epidemiol* 1999;150:312–20. <https://doi.org/10.1093/oxfordjournals.aje.a010004>
184. Poole CJ, Shakespeare AT. Should sewage workers and carers for people with learning disabilities be vaccinated for hepatitis A? *BMJ* 1993;306:1102. <https://doi.org/10.1136/bmj.306.6885.1102>
185. Trout D, Mueller C, Venczel L, Krake A. Evaluation of occupational transmission of hepatitis A virus among wastewater workers. *J Occup Environ Med* 2000;42:83–7. <https://doi.org/10.1097/00043764-200001000-00020>
186. Venczel L, Brown S, Frumkin H, Simmonds-Diaz J, Deitchman S, Bell BP. Prevalence of hepatitis A virus infection among sewage workers in Georgia. *Am J Ind Med* 2003;43:172–8. <https://doi.org/10.1002/ajim.10174>
187. Weldon M, VanEgdom MJ, Hendricks KA, Regner G, Bell BP, Sehulster LM. Prevalence of antibody to hepatitis A virus in drinking water workers and wastewater workers in Texas from 1996 to 1997. *J Occup Environ Med* 2000;42:821–6. <https://doi.org/10.1097/00043764-200008000-00011>
188. CDC. Interim immunization recommendations for individuals displaced by a disaster. Atlanta, GA: US Department of Health and Human Services, CDC. <https://www.cdc.gov/disasters/disease/vacceredisplaced.html>

189. Bloch AB, Stramer SL, Smith JD, et al. Recovery of hepatitis A virus from a water supply responsible for a common source outbreak of hepatitis A. *Am J Public Health* 1990;80:428–30. <https://doi.org/10.2105/AJPH.80.4.428>
190. Bowen GS, McCarthy MA. Hepatitis A associated with a hardware store water fountain and a contaminated well in Lancaster County, Pennsylvania, 1980. *Am J Epidemiol* 1983;117:695–705.
191. Bergeisen GH, Hinds MW, Skaggs JW. A waterborne outbreak of hepatitis A in Meade County, Kentucky. *Am J Public Health* 1985;75:161–4. [10.2105/ajph.75.2.161](https://doi.org/10.2105/ajph.75.2.161)
192. Mahoney FJ, Farley TA, Kelso KY, Wilson SA, Horan JM, McFarland LM. An outbreak of hepatitis A associated with swimming in a public pool. *J Infect Dis* 1992;165:613–8. <https://doi.org/10.1093/infdis/165.4.613>
193. De Serres G, Cromeans TL, Levesque B, et al. Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. *J Infect Dis* 1999;179:37–43. <https://doi.org/10.1086/314565>
194. Friedman LS, O'Brien TF, Morse LJ, et al. Revisiting the Holy Cross football team hepatitis outbreak (1969) by serological analysis. *JAMA* 1985;254:774–6. <https://doi.org/10.1001/jama.1985.03360060076029>
195. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States—implications for vaccination strategies. *J Infect Dis* 1998;178:1579–84. <https://doi.org/10.1086/314518>
196. Shaw FE Jr, Sudman JH, Smith SM, et al. A community-wide epidemic of hepatitis A in Ohio. *Am J Epidemiol* 1986;123:1057–65. <https://doi.org/10.1093/oxfordjournals.aje.a114334>
197. Dentinger CM, Bower WA, Nainan OV, et al. An outbreak of hepatitis A associated with green onions. *J Infect Dis* 2001;183:1273–6. <https://doi.org/10.1086/319688>
198. Rosenblum LS, Mirkin IR, Allen DT, Safford S, Hadler SC. A multifocal outbreak of hepatitis A traced to commercially distributed lettuce. *Am J Public Health* 1990;80:1075–9. <https://doi.org/10.2105/AJPH.80.9.1075>
199. CDC. Hepatitis A outbreak associated with green onions at a restaurant—Monaca, Pennsylvania, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:1155–7.
200. Wheeler C, Vogt TM, Armstrong GL, et al. An outbreak of hepatitis A associated with green onions. *N Engl J Med* 2005;353:890–7. <https://doi.org/10.1056/NEJMoa050855>
201. Desenclos JC, Klontz KC, Wilder MH, Nainan OV, Margolis HS, Gunn RA. A multistate outbreak of hepatitis A caused by the consumption of raw oysters. *Am J Public Health* 1991;81:1268–72. <https://doi.org/10.2105/AJPH.81.10.1268>
202. US Food and Drug Administration. Vaccines licensed for use in the United States. Silver Spring, MD: US Food and Drug Administration. <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>
203. Armstrong ME, Giesa PA, Davide JP, et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. *J Hepatol* 1993;18(Suppl 2):S20–6. [https://doi.org/10.1016/S0168-8278\(05\)80373-3](https://doi.org/10.1016/S0168-8278(05)80373-3)
204. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. *Vaccine* 1992;10(Suppl 1):S99–101. [https://doi.org/10.1016/0264-410X\(92\)90557-Z](https://doi.org/10.1016/0264-410X(92)90557-Z)
205. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2018. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>
206. Ragni MV, Lusher JM, Koerper MA, Manco-Johnson M, Krause DS. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. *Haemophilia* 2000;6:98–103. <https://doi.org/10.1046/j.1365-2516.2000.00386.x>
207. Linglöff T, van Hattum J, Kaplan KM, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. *Vaccine* 2001;19:3968–71. [https://doi.org/10.1016/S0264-410X\(01\)00134-7](https://doi.org/10.1016/S0264-410X(01)00134-7)
208. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. *Vaccine* 2000;18:1074–80. [https://doi.org/10.1016/S0264-410X\(99\)00354-0](https://doi.org/10.1016/S0264-410X(99)00354-0)
209. Knöll A, Hottenträger B, Kainz J, Bretschneider B, Jilg W. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. *Vaccine* 2000;18:2029–32. [https://doi.org/10.1016/S0264-410X\(99\)00524-1](https://doi.org/10.1016/S0264-410X(99)00524-1)
210. Plotkin SA. Correlates of protection induced by vaccination. *Clin Vaccine Immunol* 2010;17:1055–65. <https://doi.org/10.1128/CVI.00131-10>
211. Nalin D, Brown L, Kuter B, et al. Inactivated hepatitis A vaccine in childhood: implications for disease control. *Vaccine* 1993;11(Suppl 1):S15–7. [https://doi.org/10.1016/0264-410X\(93\)90152-N](https://doi.org/10.1016/0264-410X(93)90152-N)
212. Stapleton JT, Jansen R, Lemon SM. Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. *Gastroenterology* 1985;89:637–42. [https://doi.org/10.1016/0016-5085\(85\)90462-7](https://doi.org/10.1016/0016-5085(85)90462-7)
213. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. *Clin Infect Dis* 1992;14:580–6. <https://doi.org/10.1093/clinids/14.2.580>
214. Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. *J Hepatol* 1993;18(Suppl 2):S15–9. [https://doi.org/10.1016/S0168-8278\(05\)80372-1](https://doi.org/10.1016/S0168-8278(05)80372-1)
215. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. *J Infect Dis* 1995;171(Suppl 1):S44–9. https://doi.org/10.1093/infdis/171.Supplement_1.S44
216. Shouval D, Ashur Y, Adler R, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. *Vaccine* 1993;11(Suppl 1):S9–14. [https://doi.org/10.1016/0264-410X\(93\)90151-M](https://doi.org/10.1016/0264-410X(93)90151-M)
217. Grifols. Treating with GamaSTAN (immune globulin [human]). Los Angeles, CA: Grifols, 2019. <https://www.hypermunes.com/en/hcp/gamastan-hepatitis-a>
218. Nelson NP. Updated dosing instructions for immune globulin (Human) GamaSTAN S/D for hepatitis A virus prophylaxis. *MMWR Morb Mortal Wkly Rep* 2017;66:959–60. <https://doi.org/10.15585/mmwr.mm6636a5>
219. Tejada-Strop A, Costafreda MI, Dimitrova Z, Kaplan GG, Teo CG. Evaluation of potencies of immune globulin products against hepatitis A. *JAMA Intern Med* 2017;177:430–2. <https://doi.org/10.1001/jamainternmed.2016.9057>
220. Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. *Pediatr Infect Dis J* 2007;26:116–22. <https://doi.org/10.1097/01.inf.0000253253.85640.cc>
221. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. *Pediatr Infect Dis J* 2000;19:1045–52. <https://doi.org/10.1097/00006454-200011000-00004>
222. Letson GW, Margolis HS. Hepatitis A vaccination in infants: the ultimate solution to a long-standing public health problem. *Curr Pediatr Rev* 2007;3:11–9. <https://doi.org/10.2174/15733960779941589>

223. Lieberman J, Marcy S, Partridge S, Ward J, editors. Hepatitis A vaccine in infants: effect of maternal antibodies on the antibody response [Program and abstracts]. Presented at the 36th annual Infectious Diseases Society of America meeting. Alexandria, VA: Infectious Diseases Society of America; 1998.
224. Piazza M, Safary A, Vegnente A, et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. *Vaccine* 1999;17:585–8. [https://doi.org/10.1016/S0264-410X\(98\)00237-0](https://doi.org/10.1016/S0264-410X(98)00237-0)
225. Sharapov UM, Bulkow LR, Negus SE, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. *Hepatology* 2012;56:516–22. <https://doi.org/10.1002/hep.25687>
226. Troisi CL, Hollinger FB, Krause DS, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. *Vaccine* 1997;15:1613–7. [https://doi.org/10.1016/S0264-410X\(97\)00199-0](https://doi.org/10.1016/S0264-410X(97)00199-0)
227. Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. *J Infect Dis* 1995;171(Suppl 1):S70–2. https://doi.org/10.1093/infdis/171.Supplement_1.S70
228. Horng YC, Chang MH, Lee CY, Safary A, Andre FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. *Pediatr Infect Dis J* 1993;12:359–62. <https://doi.org/10.1097/00006454-199305000-00001>
229. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. *J Infect Dis* 1995;171:676–9. <https://doi.org/10.1093/infdis/171.3.676>
230. Nalin D. VAQTA™: hepatitis A vaccine, purified inactivated. *Drugs Future* 1995;20:24–9. <https://doi.org/10.1358/dof.1995.020.01.279550>
231. Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. *Expert Rev Vaccines* 2005;4:459–71. <https://doi.org/10.1586/14760584.4.4.459>
232. Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines—VAQTA and HAVRIX—in young adults. *Vaccine* 1999;17:2290–6. [https://doi.org/10.1016/S0264-410X\(98\)00480-0](https://doi.org/10.1016/S0264-410X(98)00480-0)
233. Findor JA, Cañero Velasco MC, Mutti J, Safary A. Response to hepatitis A vaccine in children after a single dose with a booster administration 6 months later. *J Travel Med* 1996;3:156–9. <https://doi.org/10.1111/j.1708-8305.1996.tb00730.x>
234. Van Der Meeren O, Crasta P, de Ridder M. A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults. *Hum Vaccin Immunother* 2015;11:1729–34. <https://doi.org/10.1080/21645515.2015.1045167>
235. Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. *J Med Virol* 1994;44:443–5. <https://doi.org/10.1002/jmv.1890440424>
236. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. *JAMA* 1994;271:1328–34. <https://doi.org/10.1001/jama.1994.03510410040030>
237. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. *N Engl J Med* 1992;327:453–7. <https://doi.org/10.1056/NEJM199208133270702>
238. Spradling PR, Bulkow LR, Negus SE, Homan C, Bruce MG, McMahon BJ. Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up. *Hepatology* 2016;63:703–11. <https://doi.org/10.1002/hep.28375>
239. Plumb ID, Bulkow LR, Bruce MG, et al. Persistence of antibody to hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska. *J Viral Hepat* 2017;24:608–12. <https://doi.org/10.1111/jvh.12676>
240. Mosites E, Gounder P, Snowball M, et al. Hepatitis A vaccine immune response 22 years after vaccination. *J Med Virol* 2018;90:1418–22. <https://doi.org/10.1002/jmv.25197>
241. Raczniak GA, Thomas TK, Bulkow LR, et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. *Vaccine* 2013;31:2152–5. <https://doi.org/10.1016/j.vaccine.2013.02.048>
242. Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. *Vaccine* 2014;32:1507–13. <https://doi.org/10.1016/j.vaccine.2013.10.088>
243. Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. *Vaccine* 2015;33:5723–7. <https://doi.org/10.1016/j.vaccine.2015.07.008>
244. Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. *Int J Infect Dis* 2013;17:e939–44. <https://doi.org/10.1016/j.ijid.2013.04.012>
245. Melgaço JG, Morgado LN, Santiago MA, et al. A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection. *Vaccine* 2015;33:3813–20. <https://doi.org/10.1016/j.vaccine.2015.06.099>
246. McMahon BJ, Beller M, Williams J, Schloss M, Tanttala H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. *Arch Pediatr Adolesc Med* 1996;150:733–9. <https://doi.org/10.1001/archpedi.1996.02170320079014>
247. Brito WI, Alves-Junior ER, Oliveira RM, Souto FJD. Initial evaluation of universal immunization with a single dose against hepatitis A virus in Central Brazil. *Braz J Infect Dis* 2018;22:166–70. <https://doi.org/10.1016/j.bjid.2018.04.001>
248. Souto FJD, de Brito WI, Fontes CJF. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. *Vaccine* 2019;37:771–5. <https://doi.org/10.1016/j.vaccine.2018.12.054>
249. Uruña A, González JE, Rearte A, et al. Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination. *Pediatr Infect Dis J* 2016;35:1339–42. <https://doi.org/10.1097/INF.0000000000001322>
250. Uruña A, González J, Carrega ME, et al. Single-dose universal hepatitis A immunization in 1-year-old infants in Argentina: high prevalence of protective antibodies up to 11 years following vaccination. *Open Forum Infect Dis* 2017;4(Suppl 1):S320. <https://doi.org/10.1093/ofid/ofx163.753>
251. Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. *J Pediatr* 2004;144:327–32. <https://doi.org/10.1016/j.jpeds.2003.11.030>
252. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. *Pediatr Infect Dis J* 2003;22:354–9. <https://doi.org/10.1097/01.inf.0000059446.52063.b9>
253. Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakök K. Hepatitis A booster vaccine in children after infant immunization. *Pediatr Infect Dis J* 2002;21:727–30. <https://doi.org/10.1097/00006454-200208000-00006>
254. Lieberman JM, Chang SJ, Partridge S, et al. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. *Pediatr Infect Dis J* 2002;21:347–8. <https://doi.org/10.1097/00006454-200204000-00017>
255. Wagner G, Lavanchy D, Darioli R, et al. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. *Vaccine* 1993;11:1027–32. [https://doi.org/10.1016/0264-410X\(93\)90128-K](https://doi.org/10.1016/0264-410X(93)90128-K)

256. Walter EB, Hornick RB, Poland GA, et al. Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. *Vaccine* 1999;17:1468–73. [https://doi.org/10.1016/S0264-410X\(98\)00370-3](https://doi.org/10.1016/S0264-410X(98)00370-3)
257. Fritzsche C, Bergmann L, Loebermann M, Glass A, Reisinger EC. Immune response to hepatitis A vaccine in patients with HIV. *Vaccine* 2019;37:2278–83. <https://doi.org/10.1016/j.vaccine.2019.02.064>
258. Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to hepatitis A vaccination in immunocompromised travelers. *J Infect Dis* 2015;212:378–85. <https://doi.org/10.1093/infdis/jiv060>
259. Garcia Garrido HM, Veurink AM, Leeftang M, Spijker R, Goorhuis A, Grobusch MP. Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis. *Travel Med Infect Dis* 2019;32:101479. <https://doi.org/10.1016/j.tmaid.2019.101479>
260. Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. *Hum Vaccin Immunother* 2015;11:2582–98. <https://doi.org/10.1080/21645515.2015.1055424>
261. Weinberg A, Gona P, Nachman SA, et al; Pediatric AIDS Clinical Trials Group 1008 Team. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. *J Infect Dis* 2006;193:302–11. <https://doi.org/10.1086/498979>
262. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. *J Infect Dis* 1997;176:1064–7. <https://doi.org/10.1086/516512>
263. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. *AIDS* 2005;19:1702–4. <https://doi.org/10.1097/01.aids.0000186815.99993.55>
264. Gouvea AF, De Moraes-Pinto MI, Ono E, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. *Clin Infect Dis* 2005;41:544–8. <https://doi.org/10.1086/432055>
265. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. *Transplantation* 2001;72:272–6. <https://doi.org/10.1097/00007890-200107270-00019>
266. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. *Am J Gastroenterol* 1999;94:1601–4. <https://doi.org/10.1111/j.1572-0241.1999.01150.x>
267. Ferreira CT, da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. *J Pediatr Gastroenterol Nutr* 2003;37:258–61. <https://doi.org/10.1097/00005176-200309000-00011>
268. Keffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. *Hepatology* 1998;27:881–6. <https://doi.org/10.1002/hep.510270336>
269. Lee SD, Chan CY, Yu MI, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. *J Med Virol* 1997;52:215–8. [https://doi.org/10.1002/\(SICI\)1096-9071\(199706\)52:2<215::AID-JMV16>3.0.CO;2-J](https://doi.org/10.1002/(SICI)1096-9071(199706)52:2<215::AID-JMV16>3.0.CO;2-J)
270. Majda-Stanislawski E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. *Pediatr Infect Dis J* 2004;23:571–4. <https://doi.org/10.1097/01.inf.0000130076.33497.6c>
271. Stark K, Günther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. *J Infect Dis* 1999;180:2014–7. <https://doi.org/10.1086/315125>
272. Günther M, Stark K, Neuhaus R, Reinke P, Schröder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. *Transplantation* 2001;71:477–9. <https://doi.org/10.1097/00007890-200102150-00023>
273. Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adsorbed hepatitis A vaccine in healthy adults. *Vaccine* 1997;15:1157–61. [https://doi.org/10.1016/S0264-410X\(96\)00310-6](https://doi.org/10.1016/S0264-410X(96)00310-6)
274. Tong MJ, Co RL, Bellak C. Hepatitis A vaccination. *West J Med* 1993;158:602–5.
275. Link-Gelles R, Hofmeister MG, Nelson NP. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. *Vaccine* 2018;36:2745–50. <https://doi.org/10.1016/j.vaccine.2018.04.015>
276. Postmarketing reporting of adverse experiences. 21 CFR Sect. 600.80 (2010). <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=600.80>
277. Moro PL, Museru OI, Niu M, Lewis P, Broder K. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. *Am J Obstet Gynecol* 2014;210:561:e1–6.
278. Groom HC, Smith N, Irving SA, et al. Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. *Vaccine* 2019;37:6648–55. <https://doi.org/10.1016/j.vaccine.2019.09.043>
279. Bienzle U, Bock HL, Kruppenbacher JP, Hofmann F, Vogel GE, Clemens R. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other “travellers” vaccines with the immune response. *Vaccine* 1996;14:501–5. [https://doi.org/10.1016/0264-410X\(95\)00224-O](https://doi.org/10.1016/0264-410X(95)00224-O)
280. Gil A, González A, Dal-Ré R, Calero JR. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults. *Vaccine* 1996;14:1028–30. [https://doi.org/10.1016/0264-410X\(96\)00059-X](https://doi.org/10.1016/0264-410X(96)00059-X)
281. Jong EC, Kaplan KM, Eves KA, Taddeo CA, Lakkis HD, Kuter BJ. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. *J Travel Med* 2002;9:66–70. <https://doi.org/10.2310/7060.2002.21955>
282. Ambrosch F, André FE, Delem A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. *Vaccine* 1992;10(Suppl 1):S142–5. [https://doi.org/10.1016/0264-410X\(92\)90570-A](https://doi.org/10.1016/0264-410X(92)90570-A)
283. Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. *Vaccine* 2001;19:4710–9. [https://doi.org/10.1016/S0264-410X\(01\)00240-7](https://doi.org/10.1016/S0264-410X(01)00240-7)
284. Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a *Haemophilus influenzae* type b conjugate vaccine in infants aged 12–18 months. *Vaccine* 2005;23:2602–6. <https://doi.org/10.1016/j.vaccine.2004.11.062>
285. Petrecz M, Acosta CJ, Klopfer SO, et al. Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines. *Hum Vaccin Immunother* 2019;15:426–32. <https://doi.org/10.1080/21645515.2018.1530934>
286. Rein DB, Hicks KA, Wirth KE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. *Pediatrics* 2007;119:e12–21. <https://doi.org/10.1542/peds.2006-1573>
287. Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. *Prev Med* 2001;33:639–45. <https://doi.org/10.1006/pmed.2001.0938>
288. Hankin-Wei A, Rein DB, Hernandez-Romieu A, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. *Vaccine* 2016;34:4243–9. <https://doi.org/10.1016/j.vaccine.2016.06.040>

289. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. *MMWR Surveill Summ* 2017;66. <https://doi.org/10.15585/mmwr.ss6611a1>
290. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2013;62(No. RR-4).
291. Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. *Can J Infect Dis Med Microbiol* 2008;19:197–202. <https://doi.org/10.1155/2008/410362>
292. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Washington, DC: US Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
293. Tseng YT, Chang SY, Liu WC, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. *Hepatology* 2013;57:1734–41. <https://doi.org/10.1002/hep.26210>
294. Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. *J Viral Hepat* 2006;13:81–6. <https://doi.org/10.1111/j.1365-2893.2005.00658.x>
295. Brennan J, Moore K, Sizemore L, et al. Notes from the field: acute hepatitis A virus infection among previously vaccinated persons with HIV infection—Tennessee, 2018. *MMWR Morb Mortal Wkly Rep* 2019;68:328–9. <https://doi.org/10.15585/mmwr.mm6814a3>
296. Koff RS. Hepatitis A. *Lancet* 1998;351:1643–9. [https://doi.org/10.1016/S0140-6736\(98\)01304-X](https://doi.org/10.1016/S0140-6736(98)01304-X)
297. Victor JC, Surdina TY, Suleimeova SZ, Favorov MO, Bell BP, Monto AS. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. *Epidemiol Infect* 2006;134:492–7. <https://doi.org/10.1017/S0950268805005194>
298. Smith D, Huynh C, Moore AJ, et al. Herd immunity likely protected the men who have sex with men in recent hepatitis A outbreak in San Diego CA. *Clin Infect Dis* 2018;25:25.
299. Peak CM, Stous SS, Healy JM, et al. Homelessness and hepatitis A—San Diego County, 2016–2018. *Clin Infect Dis* 2019;ciz788.
300. Wooten DA. Forgotten but not gone: learning from the hepatitis A outbreak and public health response in San Diego. *Top Antivir Med* 2019;26:117–21.
301. James TL, Aschkenasy M, Eliseo LJ, Olshaker J, Mehta SD. Response to hepatitis A epidemic: emergency department collaboration with public. *J Emerg Med* 2009;36:412–6.
302. Moro PL, Arana J, Marquez PL, et al. Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017. *Vaccine* 2019;37:3730–4. <https://doi.org/10.1016/j.vaccine.2019.04.088>
303. Iwarson S, Lindh M, Widerström L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. *J Travel Med* 2004;11:120–1. <https://doi.org/10.2310/7060.2004.17079>
304. Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. *Vaccine* 2003;21:3208–11. [https://doi.org/10.1016/S0264-410X\(03\)00250-0](https://doi.org/10.1016/S0264-410X(03)00250-0)
305. Hornick R, Tucker R, Kaplan KM, et al. A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. *Vaccine* 2001;19:4727–31. [https://doi.org/10.1016/S0264-410X\(01\)00224-9](https://doi.org/10.1016/S0264-410X(01)00224-9)
306. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. *MMWR Recomm Rep* 2018;67(No. RR-1). <https://doi.org/10.15585/mmwr.rr6701a1>
307. Bryan JP, Henry CH, Hoffman AG, et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. *Vaccine* 2000;19:743–50. [https://doi.org/10.1016/S0264-410X\(00\)00301-7](https://doi.org/10.1016/S0264-410X(00)00301-7)
308. Connor BA, Phair J, Sack D, et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. *Clin Infect Dis* 2001;32:396–401. <https://doi.org/10.1086/318522>
309. CDC. FDA approval of an alternate dosing schedule for a combined hepatitis A and B vaccine (Twinrix®). *MMWR Morb Mortal Wkly Rep* 2007;56:1057.
310. Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. *Vaccine* 2002;20:1157–62. [https://doi.org/10.1016/S0264-410X\(01\)00432-7](https://doi.org/10.1016/S0264-410X(01)00432-7)

Advisory Committee on Immunization Practices

Membership as of June 27, 2019

Chair: José R. Romero, MD, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas.

Executive Secretary: Amanda Cohn, MD, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.

Members: Robert Atmar, MD, Baylor College of Medicine, Houston, Texas; Kevin A. Ault, MD, University of Kansas Medical Center, Kansas City, Kansas; Henry Bernstein, DO, Zucker School of Medicine at Hofstra/Northwell Cohen Children's Medical Center, New Hyde Park, New York; Echezona Ezeanolue, MD, University of Nevada, Las Vegas, Nevada; Sharon E. Frey, MD, Saint Louis University Medical School, Saint Louis, Missouri; Paul Hunter, MD, City of Milwaukee Health Department, Milwaukee, Wisconsin; Grace M. Lee, MD, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, California; Veronica V. McNally, JD, Franny Strong Foundation, West Bloomfield, Michigan; Kelly Moore, MD, Vanderbilt University School of Medicine, Nashville, Tennessee; José R. Romero, MD, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas; David Stephens MD, Emory University, Atlanta, Georgia; Peter Szilagyi, MD, University of California, Los Angeles (UCLA), Los Angeles, California; Helen Keipp Talbot, MD, Vanderbilt University, Nashville, Tennessee; Emmanuel (Chip) Walter Jr., MD, Duke University School of Medicine, Durham, North Carolina.

Ex Officio Members: Eric Deussing, MD, Department of Defense; Mary Beth Hance, Centers for Medicare and Medicaid Services; Jane Kim, MD, Department of Veterans Affairs; Thomas Weiser, MD, Indian Health Service; John Beigel, MD, National Institutes of Health; Narayan Nair, MD, Health Resources and Services Administration; Doran Fink, MD, PhD, Food and Drug Administration; Tammy Beckham, National Vaccine Program Office.

Liaison Representatives: American Academy of Family Physicians, Pamela Rockwell, DO, Ann Arbor, Michigan; American Academy of Pediatrics, Red Book Editor, David Kimberlin, MD, Birmingham, Alabama; American Academy of Pediatrics, Yvonne Maldonado, MD, Stanford, California; American Academy of Physician Assistants, Marie-Michèle Léger, MPH, Alexandria, Virginia; American College Health Association, Susan Even, MD, Columbia, Missouri; American College of Nurse-Midwives, Carol Hayes, MPH, Atlanta, Georgia; American College of Nurse-Midwives Alternate, Pamela Meharry, PhD, Chicago, Illinois; American College of Obstetricians and Gynecologists, Linda O'Neal Eckert, MD, Seattle, Washington; American College of Physicians, Jason Goldman, MD, Boca Raton, Florida; American Geriatrics Society, Kenneth Schmader, MD, Durham, North Carolina; American Health Insurance Plans, Mark Netoskie, MD, Houston, Texas; American Immunization Registry Association, Rebecca Coyle, MEd, Washington DC; American Medical Association, Sandra Adamson Fryhofer, MD, Atlanta, Georgia; American Nurses Association, Charles (Chad) Rittle, DNP, Pittsburgh, Pennsylvania; American Osteopathic Association, Stanley Grogg, DO, Tulsa, Oklahoma; American Pharmacists Association, Stephan L. Foster, PharmD, Memphis, Tennessee; Association of Immunization Managers, Christine Finley, MPH, Burlington, Vermont; Association for Prevention and Teaching Research, Paul McKinney, MD, Louisville, Kentucky; Association of State and Territorial Health Officials, Nathaniel Smith, MD, Little Rock, Arkansas; Biotechnology Industry Organization, Phyllis Arthur, MBA, District of Columbia; Council of State and Territorial Epidemiologists, Christine Hahn, MD, Boise, Idaho; Canadian National Advisory Committee on Immunization, Caroline Quach, MD, Montreal, Québec, Canada; Infectious Diseases Society of America (IDSA), Carol Baker, MD, Houston, Texas; National Association of County and City Health Officials, Matthew Zahn, MD, Santa Ana, California; National Association of County and City Health Officials, Jeffrey Duchin, MD, Seattle, Washington; National Association of Pediatric Nurse Practitioners, Patricia Stinchfield, MS, St. Paul, Minnesota; National Foundation for Infectious Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Luis Duran, MD, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; Pediatric Infectious Diseases Society, Sean O'Leary, MD, Aurora, Colorado; Pediatric Infectious Diseases Society Alternate, Mark Sawyer, MD, San Diego, California; Pharmaceutical Research and Manufacturers of America, David Johnson, MD, Swiftwater, Pennsylvania; Society for Adolescent Health and Medicine, Amy Middleman, MD, Oklahoma City, Oklahoma; Society for Healthcare Epidemiology of America, David J. Weber, MD, Chapel Hill, North Carolina.

ACIP Hepatitis Vaccines Work Group

Membership as of June 27, 2019

Kelly L. Moore, MD, Nashville, Tennessee (chair). Natali Aziz, MD, Stanford, California; Sharon Balter, MD, Los Angeles, California; Elizabeth Barnett, MD, Boston, Massachusetts; Susan Even, MD, Columbia, Missouri; Darci Everett, MD, Silver Spring, Maryland; Echezona Ezeanolue, MD, Las Vegas, Nevada; Christine Finley, Burlington, Vermont; Robert Frenck, MD, Cincinnati, Ohio; Sharon Frey, MD, St. Louis, Missouri; Kathleen Harriman, PhD, Richmond, California; Susan Lett, MD, Jamaica Plain, Massachusetts; Marian Major, PhD, Silver Spring, Maryland; Brian McMahon, MD, Anchorage, Alaska; David Nace, MD, Pittsburgh, Pennsylvania; Arthur Reingold, MD, Berkeley, California; Pamela Rockwell, DO, Ann Arbor, Michigan; José R. Romero, MD, Little Rock, Arkansas; Jennifer Rosen, MD, New York City, New York; Ann Thomas, MD, Portland, Oregon; David Weber, MD, Chapel Hill, North Carolina; Matthew Zahn, MD, Orange, California; Jennifer Zipprich, PhD, Richmond, California.

Work Group Contributors

Maria Cano, MD; Mona Doshani, MD; Penina Haber, MPH; Aaron M. Harris, MD; Beth Hibbs, MPH; Megan G. Hofmeister, MD; David Kim, MD; Alaya Koneru, MPH; Andrew Kroger, MD; Noele P. Nelson, MD, PhD; Jeff Nemhauser, MD; Tina Objio, MSN, MHA; Sarah Schillie, MD; Philip Spradling, MD; John Weiser, MD; Tureka Watson, MS; Mark K. Weng, MD, CDC.

Appendix A: Provider Guidance for Preexposure Protection for International Travelers Aged ≥ 12 Months

Hepatitis A (HepA) vaccination administered with the appropriate dose and schedule is preferred to immune globulin (IG) for preexposure protection for travelers aged ≥ 12 months. One dose of single-antigen HepA vaccine administered at any time before departure might provide adequate protection for most healthy persons (1). However, single-dose long-term protection data are limited, and limited data are available for other populations (e.g., immunocompromised) or other HepA vaccine formulations (i.e., Twinrix). For unvaccinated persons, the first dose of HepA vaccine should be administered as soon as travel is considered. The second dose should be administered according to the licensed schedule to complete the series. Travelers who have received a single dose of single-antigen HepA vaccine ≥ 6 months previously can receive a second dose of HepA vaccine to complete the vaccine series. Travelers who have received a single dose of single-antigen HepA vaccine within the previous 6 months do not need an additional dose for travel (1). Travelers may be administered Twinrix before travel, consisting of 3 doses administered on a 0-, 1-, and 6-month schedule. An alternate, accelerated schedule is also available for Twinrix: 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months that provides long-term protection (2).

For travelers aged >40 years, immunocompromised persons, and persons with chronic liver disease, the ability of the person to develop a protective antibody level after receipt of HepA vaccine, the magnitude of the risk for hepatitis A virus (HAV) transmission from the exposure (e.g., endemicity of hepatitis A in the area of travel), and availability of IG and vaccine should be considered in decisions to use IG in addition to vaccine (1). In addition, because of the complexity of determining HAV endemicity globally and limited data on subpopulation variation of HAV antibody (anti-HAV) seroprevalence within regions (3,4), preexposure protection against HAV infection can be considered for persons aged ≥ 12 months who are traveling to any area.

References

1. Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. *MMWR Morb Mortal Wkly Rep* 2018;67:1216–20. <https://doi.org/10.15585/mmwr.mm6743a5>
2. CDC. FDA approval of an alternate dosing schedule for a combined hepatitis A and B vaccine (Twinrix®). *MMWR Morb Mortal Wkly Rep* 2007;56:1057.
3. Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus. *Cold Spring Harb Perspect Med* [Review]. 2018;8:01.
4. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. *Int J Health Geogr* 2011;10:57. <https://doi.org/10.1186/1476-072X-10-57>

Appendix B: Provider Guidance on Risk Assessment for Hepatitis A Postexposure Prophylaxis

Postexposure Prophylaxis for Persons Exposed to Hepatitis A Virus

Healthy persons who have completed the hepatitis A (HepA) vaccination series at any time do not need additional postexposure prophylaxis (PEP) if they are exposed to hepatitis A virus (HAV). The effectiveness of PEP is greater when administered soon after exposure. Therefore, if only immune globulin (IG) (1) or only vaccine is available for a person who has been exposed, either available product should be administered as soon as possible; the person may return for the other product if it becomes available within 2 weeks of exposure. If administered simultaneously, HepA vaccine and IG should be administered in a different anatomic site (i.e., separate limbs) (2). The HepA vaccine series should be completed with a second dose at least 6 months after the first dose for long-term protection.

PEP should be administered to all persons who have not previously completed the HepA vaccine series who have been exposed or are at risk for exposure through close personal contact with a person who has serologically confirmed HAV infection (e.g., household and sexual contacts, persons using injection or noninjection drugs with the HAV-infected person, or caregivers not using appropriate personal protective equipment) (3).

Risk for HAV Transmission in Various Settings and for Various Groups

For persons exposed to HAV, considerations regarding decisions to use IG, vaccine, or both should include the ability of the person to develop a protective level of antibodies after receipt of HepA vaccine, the magnitude of the risk for HAV transmission from the exposure, and the availability of IG and vaccine (4). The severity of HAV infection and the time to develop protective antibodies increase with age (4). In general, the risk for infection after a household or sexual exposure is likely to be greater than the risk associated with a common source exposure (e.g., exposure to a contaminated food product or restaurant exposure) (5). The risk for transmission of HAV is influenced by host and environmental factors and varies considerably in different settings. For example, without PEP, secondary attack rates of 20%–50% have been reported in households, with higher rates of transmission occurring from infected young children than from infected adolescents and adults (6–8). In contrast, attack rates among patrons of food service establishments who have been exposed to HAV-infected

food handlers are generally low (5,9–12). Given the difficulty in determining precise timing and extent of exposure and potential repeated exposures, as well as concerns over the administration and availability of IG (1,11), risk-based provider guidance is provided below.

Child care centers. PEP should be administered to all previously unvaccinated staff members and attendees of child care centers or institutions if 1) one or more cases of HAV infection are recognized in children or 2) cases are recognized in two or more households of center attendees. If one or more cases of HAV infection occur among employees, PEP for other staff and attendees should be considered based on the duties, hygienic practices, and presence of symptoms at work. In centers that do not provide care to children who wear diapers, PEP can be considered only for care center contacts of the index patient (3).

Common-source food exposure and food handlers. Because common-source transmission to patrons is unlikely (5,9,11,12), administering PEP to patrons of food establishments staffed by an HAV-infected person typically is not indicated. If, during the time when the food handler was likely to be infectious, the food handler both directly handled uncooked or cooked foods without gloves and had diarrhea or poor hygienic practices, the risk for an individual patron remains low; however, PEP may be considered for persons who have potentially been exposed (patrons or co-workers of the infected food handler during the time the food handler was symptomatic and worked) (5,11). PEP in this scenario should generally consist of vaccination for persons aged ≥ 12 months, although IG may be considered in addition to vaccine for exposed persons who are immunocompromised or have chronic liver disease. In settings in which repeated exposures to HAV might have occurred (e.g., institutional cafeterias), consideration of HepA vaccine, IG, or both is warranted.

Settings providing services to children and adults. PEP is not routinely indicated when a single case occurs in an elementary or secondary school or an office or other work setting and the source of infection is outside of the setting. PEP should be administered to persons who have close contact with index patients if an epidemiologic investigation indicates HAV transmission has occurred (e.g., among students in a school). PEP should be considered for all previously unvaccinated residents and employees when a confirmed hepatitis A case occurs in a setting where close personal contact occurs regularly and hygiene standards are difficult to maintain (e.g., correctional facility, homeless shelter, psychiatric facility, or group home or

residential facility for persons with developmental disabilities). In a setting containing multiple enclosed units or sections (e.g., prison ward), PEP administration should be limited only to persons in the area with risk for exposure (3).

Health care institutions. Because health care personnel do not have an increased prevalence of HAV infection, HepA vaccination is not routinely recommended for health care personnel in the United States (3). When a person who has HAV infection is admitted to a hospital, staff members should not routinely be administered PEP; instead, appropriate infection control practices should be emphasized (i.e., contact precautions for diapered or incontinent patients) (13). PEP within the health care setting may be considered on a case-by-case basis if the risk for exposure to HAV is considered high. Outbreaks have been observed in neonatal intensive care units because of infants acquiring infection from transfused blood and subsequently transmitting HAV to other infants and staff (14,15). Outbreaks of hepatitis A caused by transmission from patients to health care personnel are typically associated with fecal incontinence and inadequate hand hygiene (16), although most hospitalized patients who have HAV infection are admitted after onset of jaundice, when they are beyond the point of peak infectivity (17,18). In hospitals, sharing food or beverages between patients, families, and health care personnel has been associated with HAV transmission (19,20).

Host-specific factors to consider when assessing for increased risk for HAV transmission in the health care setting include health care personnel with hepatitis A working during the infectious period or working with symptoms including diarrhea, and patients with hepatitis A who are diapered or incontinent and symptomatic, including diarrhea. Infection control considerations include poor compliance with hand hygiene, poor adherence to recommended standard and transmission-based precautions (e.g., contact precautions when caring for patients with hepatitis A who are diapered or incontinent, standard precautions for all others [<https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>]) and suboptimal cleaning and disinfection of the environment. When perceived risk for HAV exposure is high, PEP for patients or health care personnel may be considered. In a health care setting with multiple enclosed units or sections (e.g., a hospital or psychiatric facility), PEP administration may be limited to areas where potential exposures may have occurred (e.g., cardiology ward or intensive care unit).

References

1. Nelson NP. Updated dosing instructions for immune globulin (human) GamaSTAN S/D for hepatitis A virus prophylaxis. *MMWR Morb Mortal Wkly Rep* 2017;66:959–60. <https://doi.org/10.15585/mmwr.mm6636a5>

2. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC. <https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/downloads/general-recs.pdf>
3. Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. *MMWR Morb Mortal Wkly Rep* 2018;67:1216–20. <https://doi.org/10.15585/mmwr.mm6743a5>
4. Link-Gelles R, Hofmeister MG, Nelson NP. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. *Vaccine* 2018;36:2745–50. <https://doi.org/10.1016/j.vaccine.2018.04.015>
5. Fiore AE. Hepatitis A transmitted by food. *Clin Infect Dis* 2004;38:705–15. <https://doi.org/10.1086/381671>
6. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. *Am J Epidemiol* 2006;163:204–10. <https://doi.org/10.1093/aje/kwj029>
7. Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. *Pediatrics* 2000;106:E54. <https://doi.org/10.1542/peds.106.4.e54>
8. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. *Vaccine* 1992;10(Suppl 1):S15–7. [https://doi.org/10.1016/0264-410X\(92\)90533-P](https://doi.org/10.1016/0264-410X(92)90533-P)
9. Sharapov UM, Kentenyants K, Groeger J, Roberts H, Holmberg SD, Collier MG. Hepatitis A infections among food handlers in the United States, 1993–2011. *Public Health Rep* 2016;131:26–9. <https://doi.org/10.1177/003335491613100107>
10. Morey RJ, Collier MG, Nelson NP. The financial burden of public health responses to hepatitis A cases among food handlers, 2012–2014. *Public Health Rep* 2017;132:443–7. <https://doi.org/10.1177/0033354917710947>
11. Ridpath A, Reddy V, Layton M, et al. Hepatitis A cases among food handlers: a local health department response—New York City, 2013. *J Public Health Manag Pract* 2017;23:571–6. <https://doi.org/10.1097/PHH.0000000000000526>
12. Hofmeister MG, Foster MA, Montgomery MP, Gupta N. Notes from the field: assessing the role of food handlers in hepatitis A virus transmission—multiple states, 2016–2019. *MMWR Morb Mortal Wkly Rep* 2020;69(20):636–37. <https://doi.org/10.15585/mmwr.mm6920a4>
13. CDC. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. <https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html>
14. Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. *J Infect Dis* 1991;164:476–82. <https://doi.org/10.1093/infdis/164.3.476>
15. Noble RC, Kane MA, Reeves SA, Roeckel I. Posttransfusion hepatitis A in a neonatal intensive care unit. *JAMA* 1984;252:2711–5. <https://doi.org/10.1001/jama.1984.03350190013011>
16. Foster MA, Weil LM, Jin S, et al. Transmission of hepatitis A virus through combined liver-small intestine-pancreas transplantation. *Emerg Infect Dis* 2017;23:590–6. <https://doi.org/10.3201/eid2304.161532>
17. Klein BS, Michaels JA, Rytel MW, Berg KG, Davis JP. Nosocomial hepatitis A. A multinursery outbreak in Wisconsin. *JAMA* 1984;252:2716–21. <https://doi.org/10.1001/jama.1984.03350190018012>
18. Goodman RA. Nosocomial hepatitis A. *Ann Intern Med* 1985;103:452–4. <https://doi.org/10.7326/0003-4819-103-3-452>

Recommendations and Reports

19. Drusin LM, Sohmer M, Groshen SL, Spiritos MD, Senterfit LB, Christenson WN. Nosocomial hepatitis A infection in a paediatric intensive care unit. *Arch Dis Child* 1987;62:690–5. <https://doi.org/10.1136/adc.62.7.690>
20. Hanna JN, Loewenthal MR, Negel P, Wenck DJ. An outbreak of hepatitis A in an intensive care unit. *Anaesth Intensive Care* 1996;24:440–4. <https://doi.org/10.1177/0310057X9602400405>

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at <https://www.cdc.gov/mmwr/index.html>.

Readers who have difficulty accessing this PDF file may access the HTML file at https://www.cdc.gov/mmwr/volumes/69/rr/rr6905a1.htm?s_cid=rr6905a1_w. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Executive Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

MMWR and *Morbidity and Mortality Weekly Report* are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 0149-2195 (Print)